title,datetime,impact_score,sentiment,summary,article
E3 Lithium Files First Quarter 2024 Financial Statements and MD&A,2024-05-24T07:05:00.000Z,Neutral,Neutral,"E3 Lithium (OTCQX: EEMMF) released its unaudited condensed consolidated interim financial statements and Management’s Discussion and Analysis (MD&A) for Q1 2024. The documents are accessible on SEDAR+ and the company's website. The report highlights the company's financial health and operational performance, important for investors and stakeholders.",
Nidec Announces the Status of Share Repurchases and the Completion of the Share Repurchase Plan,2024-05-24T06:10:00.000Z,Low,Neutral,"Nidec  (TOKYO: 6594; OTC US: NJDCY) announced the completion of its share repurchase plan as authorized on January 24, 2024. Despite authorization to repurchase up to 2,000,000 shares (0.34% of total shares) for up to 11 billion yen from January 25 to May 24, 2024, no shares were repurchased. The company attributed this to the market share price remaining within a range deemed appropriate. The repurchase window was from May 1 to May 24, 2024, with zero shares repurchased during this period.",
Trident Royalties PLC Announces Portfolio Update: First Gold Pour at Greenstone,2024-05-24T06:00:00.000Z,Low,Very Positive,"Trident Royalties announced a significant milestone for its Greenstone Gold Mine project in Ontario, Canada, managed by Equinox Gold. The project achieved its first gold pour, producing 1,800 ounces. This marks an on-schedule achievement with all equipment operating as expected. Trident holds an offtake agreement for 100% of the gold produced at Greenstone up to 58,500 oz annually until March 2027. Greenstone is projected to produce 400,000 oz of gold annually for the first five years and an average of 360,000 oz annually over its 14-year lifespan, making it one of Canada's largest gold mines. Equinox Gold anticipates ramping up to commercial production by Q3 2024, despite recent inflationary and supply chain challenges.",
Nidec Board Authorizes Share Repurchase Plan,2024-05-24T06:15:00.000Z,Neutral,Neutral,"Nidec  (TOKYO:6594; OTC US:NJDCY) announced that its Board of Directors approved a share repurchase plan during a meeting on May 24, 2024. The company may repurchase up to 5 million shares, equivalent to 0.87% of its total issued shares, excluding treasury stock. The total repurchasable amount is capped at 35 billion yen. This repurchase is aimed at maintaining financial discipline and enabling agile capital management in response to market trends or changes in the business environment. The repurchase period spans from May 27, 2024, to May 26, 2025. As of April 30, 2024, Nidec had 574,598,568 shares issued and 21,685,900 shares held in treasury.",
Nidec Announces Annual Dividend Payout from Retained Earnings,2024-05-24T06:15:00.000Z,Low,Neutral,"Nidec  (TOKYO: 6594; OTC US: NJDCY) announced on May 24, 2024, that its Board of Directors approved a dividend payout from retained earnings. The annual dividend for the fiscal year ending March 31, 2024, is set at 75 yen per share, including a year-end dividend of 40 yen per share and an interim dividend of 35 yen per share. This represents an increase from the previous year's total annual dividend of 70 yen per share. The total dividend amount is approximately 23,003 million yen, with an effective date of June 3, 2024. Nidec emphasizes stable dividend payments and aims for a dividend payout ratio around 30% of consolidated net profit.",
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting,2024-05-24T05:00:00.000Z,Neutral,Neutral,"Innate Pharma announced that five abstracts featuring its drug candidates have been accepted for presentation at the ASCO 2024 Annual Meeting, scheduled for May 31-June 4, 2024, in Chicago. Highlights include:- Topline results of the TELLOMAK Phase 2 trial for lacutamab in mycosis fungoides, confirming promising clinical activity.- Two posters on IPH6501, the second-generation ANKET® for CD20-expressing B-cell Non-Hodgkin's Lymphoma, presenting safety, tolerability, and preliminary antineoplastic activity.- AstraZeneca's updated results for monalizumab in the Phase 2 COAST trial for stage III unresectable NSCLC.- A poster on the Phase 2 MOZART trial of monalizumab combined with durvalumab and chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.These presentations underscore Innate Pharma’s commitment to advancing cancer immunotherapy.",
"The9 Obtained Exclusive Publishing License of ""MIR M"" IP, A New Chinese Edition of Mobile and PC Game from Wemade",2024-05-24T06:00:00.000Z,Neutral,Neutral,"The9  (Nasdaq: NCTY) announced that its subsidiary, China Crown Technology, has secured an exclusive publishing license for the new MIR M game from Wemade. This agreement allows China Crown to publish and service the game in mainland China for both mobile and PC platforms. The license term is 5 years from the commercial launch, expected in early 2025, with a possible 1-year extension. The game may incorporate blockchain technology, subject to PRC regulations. The9 aims to leverage AI in game development to enhance NPCs, procedural content generation, and personalized behavior prediction.",
Transaction in Own Shares,2024-05-24T05:00:00.000Z,Low,Negative,"On 24 May 2024, Endeavour Mining announced the repurchase of 12,000 of its ordinary shares (USD 0.01 each) from Stifel Nicolaus Europe, as part of a buy-back programme initiated on 20 March 2023.The shares were bought on 23 May 2024 at prices ranging from 1,669.00 GBp to 1,696.15 GBp, with a volume-weighted average price of 1,692.63 GBp.Following the repurchase and cancellation of these shares, the total number of ordinary shares in issue is 244,859,849, which will serve as the denominator for shareholders’ voting rights calculations under the FCA's Disclosure Guidance and Transparency Rules.",
The9 Obtained Strategic Investment from Fine Vision Game Fund,2024-05-24T06:00:00.000Z,Neutral,Positive,"The9  (Nasdaq: NCTY), an established Internet company, has announced a strategic private placement agreement with Fine Vision Fund, managed by Finewill Capital. Fine Vision Fund will invest $3.5 million in The9, with an initial $2.5 million upfront and a subsequent $1 million based on predefined conditions. The agreement involves issuing Class A ordinary shares to Fine Vision Fund at a 15.6% premium for the upfront investment and a 25% premium for the second installment, based on the average closing price over the previous thirty trading days. The issued shares will be subject to a statutory lock-up period. This investment aims to leverage the synergies between traditional and Web3 games, positioning The9 as a leader in this evolving market.",
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024,2024-05-24T01:03:00.000Z,Low,Positive,"Adlai Nortye  (NASDAQ: ANL) has announced its plans to present preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) at the ASCO 2024 Annual Meeting in Chicago from May 31 to June 4, 2024. AN0025, a selective EP4 inhibitor, has shown antitumor activity by modulating macrophages and immunosuppressive myeloid cells. The study, AN0025S0104, is a single-arm, open-label, multicenter, Phase Ib trial, assessing the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or recurrent esophageal cancer (EC) and esophagogastric junction cancer. Previous studies highlighted the synergistic efficacy of AN0025 with CRT in rectal cancer. Adlai Nortye aims to address unmet patient needs through innovative oncology research.",
Azul and GOL Announce Codeshare Agreement,2024-05-24T01:55:00.000Z,Low,Very Positive,"Azul and GOL airlines announced a codeshare agreement to connect their flight networks in Brazil, effective from late June 2024. This partnership covers domestic routes exclusively operated by either airline and includes frequent flyer programs, allowing members to earn points in their preferred program. The agreement grants customers access to over 150 destinations, providing more travel options and convenient connections. With approximately 2,700 travel opportunities created, customers can purchase flights through both companies' sales channels. Combined, Azul and GOL operate around 1,500 daily departures, enhancing route availability significantly.",
Klaviyo to Present at the William Blair Growth Stock Conference,2024-05-23T21:00:00.000Z,Low,Neutral,"Klaviyo (NYSE: KVYO) announced that CFO Amanda Whalen will participate in a fireside chat at the William Blair Growth Stock Conference on June 6, 2024, at 9:00 a.m. ET. The event will be webcast live, with replays available on Klaviyo's investor relations website. Klaviyo specializes in enhancing digital relationships through its SaaS platform, allowing businesses to utilize first-party data effectively. The platform supports over 350 integrations, helping clients like Good American and TaylorMade engage and retain customers through tailored messaging across email, SMS, and push notifications.",
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Neutral,"IN8bio announced the upcoming presentation of updated Phase 1 study results for INB-200 at the 2024 ASCO Annual Meeting. INB-200, an autologous Drug Resistant Immunotherapy (DeltEx DRI), is being evaluated as a first-line treatment for newly diagnosed glioblastoma multiforme (GBM). The study involved 23 patients and showed promising progression-free survival (PFS) rates beyond the median expected with standard treatment. There were no dose-limiting toxicities, although some patients experienced adverse events like decreased white blood cell count and fatigue. The presentation will take place on June 1, 2024.",
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024,2024-05-23T21:00:00.000Z,Low,Positive,"Evaxion Biotech announces positive data from its ongoing Phase 2 study of the personalized cancer vaccine EVX-01 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study, which combines EVX-01 with anti-PD1 therapy for advanced melanoma patients, reveals that EVX-01 induces strong and specific immune responses mediated by both CD4+ and CD8+ T-cells. Booster shots further enhance these responses without safety concerns. The vaccine demonstrated a good tolerance profile with only minor adverse events. These findings support the potential clinical benefits of EVX-01 and the precision of Evaxion’s AI-Immunology™ platform in selecting effective vaccine targets.",
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib,2024-05-23T21:00:00.000Z,Low,Positive,"Xspray Pharma presented compelling data at the ASCO Annual Meeting, highlighting significant issues in the co-medication of Proton Pump Inhibitors (PPIs) with Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia (CML) patients. The study revealed that 54% of CML patients treated with TKIs also received a PPI, with 66% of these comedications prescribed by different healthcare providers. The bioavailability of crystalline dasatinib was significantly affected, with a 96% reduction in Cmax and an 88% reduction in AUC24 when co-medicated with a PPI. To address this, Xspray plans to launch Dasynoc®, an optimized version of dasatinib, by September 2024.",
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:00:00.000Z,Low,Neutral,"Replimune Group, a clinical-stage biotech firm, is set to present at the 2024 ASCO Annual Meeting from May 31-June 4 in Chicago. The company will showcase data from two significant trials: the IGNYTE trial of RP1 combined with nivolumab in anti-PD-1 failed melanoma, and a Phase 1 trial of RP2 combined with nivolumab in advanced uveal melanoma. Additional highlights include three trial-in-progress posters for RP1 and RP2. Oral presentations will feature updated 12-month data and new biomarker results, with key sessions scheduled on June 3.",
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Negative,"Eli Lilly (NYSE: LLY) will present data on Verzenio, Retevmo, olomorasib, and imlunestrant at the 2024 ASCO Annual Meeting from May 31 to June 4 in Chicago.Key highlights include:1. Verzenio: Late-breaking outcomes from the Phase 3 postMONARCH study on HR+, HER2- breast cancer.2. Retevmo: Safety and efficacy results from the Phase 1/2 LIBRETTO-121 study for pediatric patients with RET-altered tumors.3. Olomorasib: Updated results for KRAS G12C-mutant cancer treatments.4. Imlunestrant: Early-phase data on combinations with HER2 therapy.An investor event will update Lilly's oncology strategy on June 2, 7:30 p.m. CDT, available via webcast.",
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Negative,"Genmab will present multiple abstracts at the 2024 ASCO Annual Meeting. These include studies on epcoritamab, tisotumab vedotin, and acasunlimab, showcasing their efficacy and safety across different cancers.The presentations will cover six oral and poster sessions, including the first Phase 2 study of acasunlimab in metastatic non-small cell lung cancer (mNSCLC).Genmab’s Chief Development Officer, Dr. Judith Klimovsky, highlighted the significant progress in developing antibody therapies.The meeting will be held from May 31 to June 2, 2024, in Chicago, IL, and virtually.",
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA,2024-05-23T21:00:00.000Z,Neutral,Negative,"Legend Biotech (NASDAQ: LEGN) will present new data on its CAR-T cell therapy, CARVYKTI®, for multiple myeloma at the 2024 ASCO and EHA events.Significant upcoming presentations include:Phase 2 CARTITUDE-2 study data will be presented at ASCO and EHA.Phase 3 CARTITUDE-4 study data regarding high-risk multiple myeloma will also be showcased.Key studies analyze CARVYKTI®'s effectiveness in patients with different risk profiles and those who had suboptimal responses to previous treatments.Despite positive advancements, warnings about severe side effects such as cytokine release syndrome, neurologic toxicities, and other serious adverse events were noted.",
NVIDIA Announces Upcoming Event for Financial Community,2024-05-23T21:00:00.000Z,No impact,Neutral,"NVIDIA has announced its participation in the BofA Securities Global Technology Conference on June 5, 2024, at 12:30 PM Pacific time. The event will feature a live audio webcast of NVIDIA's financial presentations, accessible via the company's investor relations website. Replays of the webcast will be available for a period of 90 days after the event.",
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced the publication of abstracts for MCLA-145 and MCLA-129 at the 2024 ASCO® Annual Meeting.On June 2, 2024, from 11:30 a.m. to 1:00 p.m. CT, a rapid oral session will present interim data from a Phase I study of MCLA-145 in advanced/metastatic solid tumors. MCLA-145 showed a disease control rate of 68% and was well-tolerated at the recommended dose of 40 mg every three weeks.On June 3, 2024, from 1:30 to 4:30 p.m. CT, a poster presentation will cover the efficacy and safety of MCLA-129 in non-small cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations. Full presentations will be available on the Merus website.",
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Merus has announced the publication of an abstract on petosemtamab combined with pembrolizumab for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). The interim clinical data from 26 patients, as of November 6, 2023, shows a 60% response rate among 10 evaluable patients. The combination was well-tolerated with no significant overlapping toxicities.The abstract will be presented at the 2024 ASCO Annual Meeting in Chicago, from May 31 to June 4, 2024. Merus will discuss the full dataset during a conference call on May 28, 2024. The company remains optimistic about the safety and efficacy of petosemtamab, particularly noting the low rate of severe adverse events and infusion-related reactions.",
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.Preliminary data from ARTISTRY-6 cohorts are expected in 2025.",
"Alibaba Group Prices US$4,500 Million Offering of Convertible Senior Notes",2024-05-24T00:09:00.000Z,Neutral,Neutral,"Alibaba Group has announced the pricing of its US$4,500 million convertible senior notes offering due 2031. The notes will bear an interest rate of 0.50% per year and will be offered primarily to qualified institutional buyers. The initial conversion rate is approximately 9.5202 ADSs per US$1,000 principal amount, with each ADS representing eight ordinary shares. Alibaba intends to use the net proceeds to repurchase its shares and fund capped call transactions aimed at reducing potential dilution. The offering is expected to close on May 29, 2024, subject to customary conditions.",
Journey Energy Inc. Reports on Voting from the 2024 Annual Shareholders Meeting,2024-05-23T23:47:00.000Z,Neutral,Neutral,"Journey Energy announced the results of its 2024 Annual Shareholders Meeting held on May 23, 2024.Shareholders approved all resolutions, including fixing the number of directors at six. Each director nominee received more than 85% of votes in favor, with Craig H. Hansen, Jenna M. Kaye, Thomas J. Mullane, Reginald S. Smith, Scott A. Treadwell, and Alex G. Verge elected.KPMG LLP was appointed as the auditor with 99.46% support. The meeting followed Section 11.3 of National Instrument 51-102.",
Wheaton Precious Metals Publishes 2023 Sustainability Report,2024-05-23T22:26:00.000Z,No impact,Positive,"Wheaton Precious Metals has published its 2023 Sustainability Report, highlighting its ESG (Environmental, Social, and Governance) commitments and achievements. The report details Wheaton's progress in integrating ESG into its operations, including recognition as a top-rated ESG performer by several organizations. Key achievements include a significant increase in emission reduction targets, improved diversity in the workforce and board, and substantial community investments totaling over US$6.9 million in 2023. The report also notes the evolution of the CSO role for better ESG oversight and the screening of all new streaming agreements for ESG risks. Wheaton's approach aligns with standards from SASB, GRI, and TCFD, with a separate Climate Change Report to be released later in 2024.",
GLG Life Tech Corporation Provides Update Regarding Delayed 2023 and 2024 Q1 Financial Filings and Events Related to Subsidiaries,2024-05-23T22:27:00.000Z,Neutral,Neutral,"GLG Life Tech  (TSX:GLG) has delayed its 2023 and 2024 Q1 financial filings, resulting in a failure-to-file cease trade order (FFCTO) issued by the British Columbia Securities Commission. The delays are due to late court orders from a Chinese court overseeing the bankruptcy of its subsidiary, Runyang. The company expects these adjustments to be favorable to its balance sheet. Management aims to complete and file these financial reports by June 17, 2024. Additionally, GLG has received shareholder approval to transfer its Runde subsidiary, which is anticipated to improve the balance sheet by CAD 67 million. The company will provide further updates at its Annual General Meeting on June 28, 2024.",
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option,2024-05-23T23:03:00.000Z,Neutral,Neutral,"The FDA's Molecular and Clinical Genetics Panel has strongly recommended the approval of Guardant Health's Shield™ blood test for colorectal cancer (CRC) screening in adults aged 45 and older at average risk. The panel's vote was 8 to 1 for safety, 6 to 3 for effectiveness, and 7 to 2 for benefits outweighing risks. Shield aims to improve CRC screening rates by offering a non-invasive alternative to stool-based tests. Shield demonstrated 83% sensitivity and 90% specificity for advanced neoplasia in the pivotal ECLIPSE study, aligning with existing non-invasive tests. The FDA is expected to make its decision later this year.",
Browning West Announces Successful Replacement of Gildan Activewear’s Entire Board of Directors with Full Eight-Member Slate,2024-05-23T21:58:00.000Z,Low,Neutral,"Browning West announced the successful replacement of Gildan Activewear's entire Board of Directors with an eight-member slate. A significant 5.7% shareholder in Gildan, Browning West's new board includes Michael Kneeland and Glenn Chamandy, who will be reinstated as CEO. Browning West highlighted the overwhelming shareholder support for the new board and criticized the previous board's resistance, which included significant financial expenditures. The new leadership aims to restore stability and enhance long-term shareholder value.",
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting,2024-05-23T22:00:00.000Z,Neutral,Positive,"Myriad Genetics will present data from seven studies at the 2024 ASCO Annual Meeting, focusing on breast cancer risk assessment and various innovative tests like the Precise™ MRD Test and MyChoice® CDx HRD Companion Diagnostic Test. Key presentations include the efficacy of Myriad’s RiskScore in predicting triple-negative breast cancer in Black women and the effectiveness of neoadjuvant combination therapy for advanced ovarian cancer. Myriad is also expanding its oncology portfolio with new products and research collaborations, and plans to launch commercial MRD and liquid biopsy testing by 2025. The MCRR registry, comprising data from over one million patients, supports transparent clinical data sharing.",
SEMIFIVE Signs MOU with Atron Technologies to Collaborate on Semiconductor Design,2024-05-23T22:00:00.000Z,Neutral,Very Positive,"SEMIFIVE, a leader in platform-based custom silicon solutions, has signed a Memorandum of Understanding (MOU) with Atron Technologies on May 23, 2024, to collaborate on semiconductor design and turnkey manufacturing. The agreement aims to expand their business in China, leveraging Atron's expertise in high-end ASIC design and SEMIFIVE's SoC platform solutions. Atron has a strong background in AI/HPC, automotive, networking, and AIoT semiconductor designs. SEMIFIVE has been expanding globally, with offices in San Jose and Shanghai. Recently, SEMIFIVE announced the mass production of an AI inference chip using its 14nm platform and commenced commercialization of an NPU chip for HPC applications using its 5nm platform.",
mCloud Provides Corporate Update,2024-05-23T22:00:00.000Z,Moderate,Neutral,"mCloud Technologies Corp., a cloud technology solutions provider, has announced significant corporate updates. The company, currently in a Strategic Process to explore strategic alternatives, will advance to its next steps in collaboration with Google Cloud. Key updates include the resignation of all independent directors and most officers, barring the CEO and Chief Growth Officer. mCloud aims to restructure and potentially sell the company or its strategic assets. The company is also addressing legacy liabilities and costs, and is involved in legal proceedings with ATB Financial and Emissions Reduction Corp.",
"Aqua Pennsylvania Files Rate Request Based on Water and Wastewater Operations, Infrastructure Improvements and Repairs Across the Commonwealth",2024-05-23T22:00:00.000Z,Low,Neutral,"Aqua Pennsylvania has filed a rate adjustment request with the Pennsylvania Public Utility Commission (PUC) to recover $953 million in infrastructure investments by the end of 2025. This marks Aqua's first rate request in almost three years. The increase aims to support the replacement of around 200 miles of aging water mains, installation of new valves and service lines, and the replacement of hundreds of fire hydrants.Aqua President Marc Lucca emphasized the need for modernizing water and wastewater infrastructure and highlighted the company's efforts to comply with new regulations and counter cyber threats. The proposed rate hike would raise the average residential water bill from $80.91 to $97.01 per month, and the wastewater bill from $81.18 to $96.10 per month.The review process can take up to nine months, with any approved changes expected to take effect by February 2025. Aqua is also seeking grants and low-interest loans to mitigate the impact on customers and offers financial assistance options for those in need.",
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting,2024-05-23T21:00:00.000Z,Moderate,Positive,"Iovance Biotherapeutics presented new clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma at the ASCO 2024 Annual Meeting. The IOV-COM-202 trial showed a 65% objective response rate (ORR) and a 30% complete response rate, with nearly all responses ongoing at a median follow-up of 21.7 months. The results support the ongoing TILVANCE-301 Phase 3 trial. Lifileucel's safety profile as a one-time treatment was favorable compared to continuous regimens. Early interim analysis of ORR could expedite regulatory approval.",
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Candel Therapeutics announced promising Phase 2 trial results for CAN-2409, combined with valacyclovir, in NSCLC patients resistant to immune checkpoint inhibitors (ICI). The median overall survival (mOS) was 20.6 months, outperforming the 11.6 months mOS of standard docetaxel-based chemotherapy. The treatment significantly increased cytotoxic and memory T cells, enhancing systemic immunity, and showed efficacy on both treated and untreated tumors. Additionally, CAN-2409 maintained a favorable safety profile, with mostly mild adverse events. These findings underscore the potential of CAN-2409 in treating advanced NSCLC and will be presented at the 2024 ASCO Annual Meeting.",
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting,2024-05-23T21:00:00.000Z,Low,Neutral,"Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, shows that WTX-124 is well-tolerated and clinically active in patients with advanced or metastatic solid tumors who have relapsed after checkpoint inhibitor therapy.Preliminary combination data with pembrolizumab indicates similar tolerability to monotherapy. Werewolf will host a webcast on June 3, 2024, to discuss the results in detail. This Phase 1/1b trial is evaluating the IL-2 INDUKINE™ molecule, aiming to address unmet medical needs in difficult-to-treat cancers.",
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting,2024-05-23T21:00:00.000Z,Low,Neutral,"Kymera Therapeutics announced new clinical data for KT-253, an MDM2 degrader, from its ongoing Phase 1 trial. The data will be presented at the ASCO Annual Meeting from May 31 to June 4, 2024.The study includes 18 patients, indicating promising results in tumor response and a favorable safety profile. Partial and complete responses were observed in patients with Merkel cell carcinoma and acute myeloid leukemia, respectively. KT-253 was well-tolerated, with common adverse events being nausea, fatigue, and headache. Further data will be shared later this year.",
MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT,2024-05-23T21:00:00.000Z,Low,Neutral,"Maquia Capital Acquisition  (Nasdaq: MAQCU) and Immersed Inc. have mutually agreed to terminate their previously announced Business Combination Agreement, effective May 20, 2024. Despite this termination, Maquia remains committed to pursuing a business combination with a suitable target. Further details will be disclosed in a Current Report on Form 8-K, available on the SEC's website.",
Power Integrations to Present at Upcoming Investor Conferences,2024-05-23T21:30:00.000Z,Low,Neutral,"Power Integrations (Nasdaq: POWI) has announced that it will present at two upcoming investor conferences. The first event is the TD Cowen 52nd Annual Technology, Media & Telecom Conference in New York on May 30 at 1:50 pm Eastern time. The second event is the Stifel Cross Sector Insight Conference in Boston on June 4 at 9:45 am Eastern time. Both presentations will be webcast live and accessible via the company's investor page at investors.power.com.",
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting,2024-05-23T21:30:00.000Z,Moderate,Neutral,"Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x) mKRAS-specific T cell response in all enrolled patients.Key findings included CD8+ and CD4+ responses in 66.7% of patients at the 4.9 mg dose, and tumor biomarker reductions in 71% of evaluable patients. Antigen-spreading, targeting non-immunizing tumor neoantigens, was observed in all patients at the 4.9 mg dose. The study supports further development, with the recommended Phase 2 dose being 10.0 mg AMP-CpG-7909 with 4.9 mg AMP-Peptides 7P.",
SSR Mining Announces Voting Results From 2024 Annual and Special Meeting of Shareholders,2024-05-23T21:25:00.000Z,Low,Neutral,"SSR Mining announced voting results from its 2024 Annual and Special Meeting of Shareholders held on May 23, 2024. All ten nominees for the board of directors were re-elected, including A.E. Michael Anglin, Rod P. Antal, and Brian R. Booth. At the meeting, shareholders also passed resolutions on executive compensation, the 2024 Share Compensation Plan, and the appointment of PricewaterhouseCoopers as the independent auditor. The non-binding advisory vote on executive compensation received 55.81% support. The 2024 Share Compensation Plan was approved with 93.22% votes in favor. PricewaterhouseCoopers was reappointed with 97.89% support.",
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers,2024-05-23T21:18:00.000Z,Neutral,Positive,"Oklo, a company specializing in fast fission clean power technology and nuclear fuel recycling, has partnered with Wyoming Hyperscale to deliver 100 megawatts of clean power to a new data center campus. They have signed a non-binding letter of intent to collaborate on a 20-year Power Purchase Agreement. This partnership aims to address the growing demand for electricity driven by global digitalization and AI adoption. Both companies are committed to providing sustainable and efficient energy solutions. The announcement underscores Oklo's dedication to advancing sustainable energy practices and supporting high-efficiency operations within the data center industry.",
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq,2024-05-23T21:18:00.000Z,Neutral,Neutral,"Fresh2 Group  (NASDAQ: FRES), a B2B e-commerce and supply chain management company in the restaurant and food industry, announced on May 23, 2024, that it received a delinquency compliance alert from Nasdaq. The alert is due to the company's failure to timely file its Form 10-Q for the period ended March 31, 2024, and its Form 10-K for the fiscal year ended December 31, 2023, with the SEC. Nasdaq has given Fresh2 60 days to submit a compliance plan, with a deadline of June 17, 2024, for the company to outline how it will meet the requirements. If the plan is accepted, Fresh2 may receive an extension until October 14, 2024. If not, the company can appeal this decision to a Hearings Panel.",
"CORRECTION – The Herzfeld Caribbean Basin Fund, Inc. Announces Distribution in Stock and Cash",2024-05-23T21:49:00.000Z,No impact,Neutral,"The Herzfeld Caribbean Basin Fund (NASDAQ: CUBA) announced a corrected schedule for its upcoming distribution in stock and cash. The revised Ex-Date is 06/03/2024. The distribution will be paid on 07/15/2024, with a per-share amount of $0.135375. Stockholders may choose to receive their distribution in cash or stock, with the total cash portion  to 20%. The rest will be distributed as common stock. The average stock price on June 27, 28, and July 1, 2024, will determine the number of shares issued. This distribution aims to strengthen the Fund's balance sheet and capitalize on future investment opportunities. The distribution includes a return of capital, meaning part of the stockholder's original investment is paid back. The Fund's policy ensures a 15% annual rate of distribution, reviewed quarterly. The policy may be amended or terminated, impacting the market price of the Fund's shares. The current distribution is solely from capital returns and not investment income or capital gains.",
"PARAMOUNT GLOBAL AND CHARTER COMMUNICATIONS ANNOUNCE NEW MULTI-YEAR AGREEMENT FOR DISTRIBUTION OF PARAMOUNT'S LINEAR NETWORKS, CBS OWNED-AND-OPERATED STATIONS AND DIRECT-TO-CONSUMER STREAMING SERVICES",2024-05-23T21:15:00.000Z,Neutral,Very Positive,"Paramount Global and Charter Communications have announced a new multi-year distribution deal for Paramount's linear networks, CBS owned-and-operated stations, and direct-to-consumer streaming services. In this agreement, ad-supported versions of Paramount+ Essential and BET+ Essential will be available at no extra cost to Spectrum TV customers. Charter will also offer Paramount's streaming services for purchase to its internet-only customers. This deal aims to add value for consumers and provide new distribution opportunities, with Spectrum continuing to carry popular networks like CBS, BET, MTV, and more. Financial terms remain undisclosed.",
Plurilock Announces Amendment to Terms of Convertible Debentures and Warrant Inducement Program and Closing of Debt Settlement,2024-05-24T00:03:00.000Z,Low,Neutral,"Plurilock Security has received TSX Venture Exchange approval to amend the terms of its unsecured convertible debentures issued in 2022. From May 27, 2024, to June 26, 2024, the conversion price of these debentures will be reduced from $2.00 to $0.25 per share. Debenture holders converting during this period will receive new warrants allowing them to purchase shares at $0.30 for one year. Additionally, Plurilock settled $218,552.50 of debt by issuing 1,092,762 units at $0.20 per unit. Each unit includes one common share and a warrant to buy an additional share at $0.25 in the first year or $0.40 in the second year. The company has also launched an investor relations campaign with Social Network Effect Communications, costing US$432,272, and clarified terms for its private placement finders' warrants.",
CubicFarm Systems Corp. Announces Closing of Private Placement,2024-05-23T23:29:00.000Z,Low,Neutral,"CubicFarm Systems announced the closing of its non-brokered private placement, issuing 2,875,000 units at C$0.20 per unit, generating gross proceeds of C$575,000. Each unit comprises one common share and one-half of a purchase warrant, allowing the holder to buy an additional share at C$0.25 within 24 months. The funds will be used for general working capital. Insider John de Jonge participated, purchasing 500,000 units, constituting a related party transaction, but exempt from formal valuation and minority approval requirements. The private placement is subject to regulatory approvals, including TSX Venture Exchange.",
LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial Results,2024-05-23T23:00:00.000Z,Moderate,Neutral,"LexinFintech Holdings  (NASDAQ: LX) reported its unaudited financial results for Q1 2024. Total loan origination was RMB58.0 billion, a 4.8% year-over-year decrease. However, the outstanding loan balance increased by 13.5% to RMB122 billion. Total operating revenue rose by 8.7% to RMB3.2 billion, while net profit was RMB202 million, a 38.4% decline from the previous year. Despite lower loan origination, asset quality improved, and funding costs reached a record low. The number of registered users grew by 10.8% to 215 million, though active users decreased by 10.8% to 4.5 million. The company maintained a conservative outlook, focusing on risk management and operational efficiency.",
Pan American Silver Releases 2023 Sustainability Report,2024-05-23T21:23:00.000Z,No impact,Neutral,"Pan American Silver (NYSE: PAAS, TSX: PAAS) has released its 2023 Sustainability Report, detailing its ESG (environment, social, and governance) achievements. Key highlights include zero fatalities, a record low injury frequency rate of 0.69, and a lowest injury severity rate of 40. The company invested $14.7 million in local communities and spent over $2 billion on wages, supplies, services, and taxes. Pan American rehabilitated 89 hectares of land, received approval for the Manantial Espejo social closure plan, and trained 100% of its security personnel in human rights. Women were hired for 24% of vacant positions. The report incorporates GRI Standards, SASB Standards, and TCFD framework. Pan American also completed the Yamana Gold acquisition, adding four new mines. Recognized by S&P Global and Sustainalytics, Pan American ranks in the top 10% for ESG performance in the Metals & Mining industry.",
NextEra Energy board declares quarterly dividend,2024-05-23T21:18:00.000Z,Low,Neutral,"The board of directors of NextEra Energy (NYSE: NEE) has declared a regular quarterly common stock dividend of $0.515 per share. This dividend will be payable on June 17, 2024, to shareholders of record as of June 3, 2024.NextEra Energy is a leading clean energy company based in Juno Beach, Florida. It owns Florida Power & Light Company, the largest electric utility in the U.S., serving approximately 12 million people. NextEra also owns NextEra Energy Resources, the largest generator of renewable energy from wind and solar globally, and operates seven commercial nuclear power units in Florida, New Hampshire, and Wisconsin.The company is recognized for its sustainability, corporate responsibility, ethics, and diversity. More details can be found on their official websites.",
"Denarius Metals Files National Instrument 43-101 Technical Report and Preliminary Feasibility Study for the Aguablanca Project in Extremadura, Spain",2024-05-23T22:55:00.000Z,Neutral,Neutral,"Denarius Metals announced the filing of a National Instrument 43-101 compliant technical report supporting its Preliminary Feasibility Study for the Aguablanca Project in Spain. The report, effective from March 24, 2024, was prepared by Resource Development Associates. This study covers Denarius' 50% stake in the Aguablanca Nickel-Copper Mineral Deposit. Investors can access the full report on Denarius Metals' website or SEDAR+.",
Graphic Packaging Holding Company Declares Quarterly Dividend,2024-05-23T21:21:00.000Z,Low,Neutral,"Graphic Packaging Holding Company (NYSE: GPK) announced a quarterly dividend of $0.10 per share of common stock. The dividend will be payable on July 5, 2024, to shareholders of record as of June 15, 2024. Based in Atlanta, Georgia, Graphic Packaging is a leading consumer packaging company focusing on renewable and recycled materials. The company operates a global network of design and manufacturing facilities, serving major brands in food, beverage, foodservice, household, and other consumer products sectors.",
Golden Entertainment Announces Repricing of Term Loan,2024-05-23T21:42:00.000Z,Low,Very Negative,"Golden Entertainment (NASDAQ: GDEN) has announced a repricing and allocation of its existing term loan credit facility, due in 2030. The amendment, pending final documentation and customary closing conditions, will reduce the applicable margin by 50 basis points. Base rate loans will now bear interest at the base rate plus 1.25%, and SOFR loans at the SOFR rate plus 2.25%. Additionally, the Term SOFR Adjustment of 10 basis points will be eliminated, resulting in a total interest rate reduction of 60 basis points. Santander and Deutsche Bank Securities served as lead arrangers, with legal counsel from Latham & Watkins and Cahill Gordon & Reindel.",
FCPT Announces Sale Leaseback of Eight Mavis Tire Operated Properties for $20 Million,2024-05-23T22:12:00.000Z,Neutral,Neutral,"Four Corners Property Trust (NYSE: FCPT) has announced the acquisition of eight Mavis Tire-operated properties for $20 million through a sale-leaseback agreement. The properties are situated in Alabama, Georgia, Louisiana, New Jersey, New York, and Tennessee. These assets will be operated under long-term, triple net leases. The transaction was priced at a cap rate consistent with previous FCPT transactions.",
Temple Tornado: U-Haul Offers 30 Days Free Self-Storage to Storm Victims,2024-05-23T23:40:00.000Z,Low,Neutral,"U-Haul Co. of North Austin is offering 30 days of free self-storage and U-Box container usage to families affected by the recent tornado in Temple, Texas. Thirteen facilities are participating in this initiative, providing essential storage solutions to help with recovery. The offer is available for new rentals and based on availability but excludes residential delivery and pick-up. U-Haul is also a recognized American Red Cross Disaster Responder, emphasizing its commitment to aiding communities during disasters.",
Gildan Board of Directors Resigns,2024-05-23T21:55:00.000Z,Low,Neutral,"Gildan Activewear (GIL) has undergone significant leadership changes with the resignation of its entire Board of Directors and the stepping down of Vince Tyra as President and CEO, effective May 23, 2024. Browning West nominees will replace the outgoing Board members. Additionally, the previously announced sale process has been canceled. This decision aligns with shareholders' feedback ahead of the May 28, 2024 Annual Meeting. The outgoing directors believe this transition is in the best interest of all stakeholders, ensuring a smooth and efficient changeover for the new Board to guide the company forward.",
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:05:00.000Z,Neutral,Neutral,"BioAtla announced promising Phase 1 clinical trial results for evalstotug, a conditionally active anti-CTLA-4 antibody, in combination with nivolumab. Key findings include prolonged progression-free survival (PFS) of over 10 months in refractory PD1 failure patients, with manageable safety profiles allowing extended treatment durations. High doses (up to 1 gram) showed positive responses, including complete and partial responses in various carcinomas. The disease control rate was 52%, and several patients remained progression-free for over a year.BioAtla plans to commence a Phase 3 trial in late 2024 for first-line metastatic BRAF-mutated melanoma, following an anticipated FDA meeting.",
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:05:00.000Z,Neutral,Neutral,"NKGen Biotech has announced interim results from its Phase 1 clinical trial of SNK02, an allogeneic NK cell therapy for advanced solid tumors, at the 2024 ASCO Annual Meeting. The trial showed that SNK02 was well-tolerated and demonstrated a stable disease response in 100% of patients completing 8 treatment cycles. The study involved five patients with refractory solid tumors, averaging four prior lines of therapy, and a median age of 64. SNK02 did not require lymphodepletion before administration and exhibited some clinical activity as a monotherapy. Adverse events were mostly mild with one Grade 3 event resolving without intervention. The company plans to continue studying SNK02 in combination with monoclonal antibodies and immune checkpoint inhibitors.",
"V2X to Participate in the Baird 2024 Global Consumer, Technology & Services Conference",2024-05-23T23:04:00.000Z,Low,Neutral,"V2X (NYSE: VVX), a leading provider of global mission solutions, will participate in the Baird 2024 Global Consumer, Technology & Services Conference.The event is scheduled for June 4, 2024, at 3:45 p.m. Eastern time in New York City. The company's management will address the conference, potentially providing insights into its operations, strategies, and future prospects.",
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting,2024-05-23T21:10:00.000Z,Neutral,Neutral,"Agenus has announced new data from a Phase 1b trial involving botensilimab and balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC). These findings, to be presented at the 2024 ASCO Annual Meeting, highlight the efficacy of BOT/BAL in metastatic sites beyond the lungs and lymph nodes, including the peritoneum, soft tissue, and brain. The trial involved 77 heavily pre-treated patients, showing overall response rates (ORR) between 18-33% and disease control rates (DCR) from 67-82%. The overall survival (OS) ranged from 20.7 months to not reached (NR). No new safety signals were reported.",
"SR BANCORP, INC. ANNOUNCES BALANCE SHEET REPOSITIONING",2024-05-23T21:55:00.000Z,Low,Negative,"SR Bancorp, the holding company for Somerset Regal Bank, announced a balance sheet repositioning strategy. The company sold $35.4 million of lower-yielding investment securities for a pre-tax realized loss of approximately $4.4 million. This sale represents most of the bank's available-for-sale portfolio. The $30.9 million proceeds will be redeployed into residential and commercial real estate mortgages, anticipated to have a positive spread differential of about 465 basis points over the sold securities. This could result in $1.4 million in additional pre-tax earnings annually. The loss is expected to be recouped within 3.27 years. The impact on shareholders' equity and book value per share is minimal. The bank’s capital levels remain well above required thresholds. The repositioning is projected to improve earnings, net interest margin, and return on assets.",
"Infobird Co., Ltd Receives Notification from Nasdaq for Failure to Timely File Form 20-F",2024-05-23T22:00:00.000Z,Neutral,Neutral,"Infobird (NASDAQ: IFBD) announced it has not filed its Form 20-F for the fiscal year ended December 31, 2023, by the May 15, 2024, deadline.Despite the delay, Infobird expects to finalize the financial statements soon. On May 20, 2024, Nasdaq notified the company of non-compliance with Listing Rule 5250(c)(1).Infobird has until July 19, 2024, to submit a compliance plan, and if accepted, they have until November 11, 2024, to file the form. The company's shares remain listed, and it intends to submit the plan by the deadline.",
Sailfish Reports Q1 2024 Results,2024-05-23T21:20:00.000Z,Low,Negative,"Sailfish Royalty Corp. (TSXV: FISH, OTCQX: SROYF) announced its Q1 2024 financial results. Key highlights include gold ounces earned from stream interests of 91, reflecting a decline from 360 in Q1 2023. Royalty revenue surged to $161,987, up from $0 in the same period last year. Total revenues stood at $357,955, down from $676,478 in Q1 2023. The company reported a gross profit of $248,088 compared to $366,181 a year ago. Notably, Sailfish achieved a net income of $148,034, a recovery from a net loss of $609,557 in Q1 2023. The firm repurchased and canceled 516,100 common shares and declared a quarterly dividend of $0.0125 per share. Subsequent to Q1, Sailfish received 13,500 ounces of silver, canceled 348,700 shares, and purchased 321,200 shares on the market.",
Chesapeake Gold Announces Agreement to Acquire Intellectual Property Rights,2024-05-23T22:26:00.000Z,Moderate,Neutral,"Chesapeake Gold Corp (TSXV: CKG, OTCQX: CHPGF) announced an agreement to acquire Intellectual Property Rights from Hycroft Mining Holding  The acquisition, valued at C$2,000,000 in cash and 1,026,518 common shares, includes patents, patent applications, and technology for leaching processes. This deal will terminate Alderley Gold Corp's existing licensing obligations, ending royalty payments and other liabilities. The transaction is anticipated to close by May 30, 2024, pending TSX Venture Exchange approval. CEO Jean-Paul Tsotsos highlighted this as a key step in Chesapeake's technological development.",
"SILVERCORP REPORTS ADJUSTED NET INCOME OF $39.3 MILLION, $0.22 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $91.6 MILLION FOR FISCAL 2024",2024-05-23T21:12:00.000Z,Neutral,Neutral,"Silvercorp Metals Inc. (TSX: SVM, NYSE American: SVM) reported adjusted net income of $39.3 million ($0.22 per share) and cash flow from operations of $91.6 million for Fiscal 2024. For Q4 Fiscal 2024, the company mined 195,160 tonnes of ore and produced approximately 1.3 million ounces of silver equivalent. Revenue for Q4 was $42.7 million, with net income of $5.5 million ($0.03 per share). For the full Fiscal 2024, Silvercorp generated revenue of $215.2 million, with a net income of $36.3 million ($0.21 per share). Operating cash flow was $91.6 million. The company’s cash cost per ounce of silver, net of by-product credits, was negative $0.38, with an all-in sustaining cost of $11.38 per ounce. Silvercorp ended Fiscal 2024 with $184.9 million in cash and equivalents. Significant investments included $45.0 million on underground development and $6.2 million on new tailings storage facilities.",
"Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024",2024-05-23T21:05:00.000Z,Low,Neutral,"Compass Therapeutics announced Phase 1 data for CTX-471, a novel CD137 agonist antibody, demonstrating anti-tumor activity in patients who progressed on PD-1 or PD-L1 inhibitors. The data will be presented at the ASCO Annual Meeting 2024. Five clinical responses were observed, including a complete response in a patient with small-cell lung cancer and partial responses in patients with melanoma and mesothelioma. CTX-471 was well tolerated, with the main dose-limiting toxicity being thrombocytopenia, which resolved. A low incidence of liver toxicity and mostly low-grade adverse events were reported. The study involved 19 patients in the dose escalation phase and 60 in the dose expansion phase.",
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany,2024-05-23T21:05:00.000Z,Neutral,Neutral,"Novocure (NASDAQ: NVCR) has announced results from the TIGER study, which investigated the use of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) in Germany. The study, conducted from August 2017 to November 2019, included 429 patients and is the largest prospective, non-interventional study of TTFields therapy to date. Key findings indicate a median overall survival of 19.6 months and a median progression-free survival of 10.2 months. The therapy was well tolerated with no increase in systemic toxicity. One-year, two-year, three-year, and four-year survival rates were 79.2%, 42.4%, 31.5%, and 27.7%, respectively. These results align with previous phase 3 EF-14 clinical trial outcomes. The data will be presented at the 2024 American Society of Clinical Oncology Annual Meeting.",
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting,2024-05-24T00:00:00.000Z,Neutral,Neutral,"HUTCHMED (China) announced it will present new and updated data from several studies at the 2024 ASCO Annual Meeting. Key highlights include the Phase II study of fruquintinib combined with sintilimab in endometrial cancer patients, showing an objective response rate (ORR) of 35.6%, disease control rate (DCR) of 88.5%, and median progression-free survival (PFS) of 9.5 months. The study supported a New Drug Application (NDA) in China. Additionally, updated data from the Phase III FRUTIGA study in gastric cancer, and data from the FRESCO and FRESCO-2 studies in colorectal cancer will be presented. Other presentations include studies on surufatinib and the ERK1/2 inhibitor HMPL-295.The ASCO Annual Meeting will take place from May 31 to June 4, 2024, in Chicago, IL, and online.",
"Century Complete Expands Fort Myers Area Offerings With LaBelle, FL Community",2024-05-23T22:51:00.000Z,No impact,Very Positive,"Century Communities announced its Century Complete brand is now selling new homes in LaBelle, FL, at Belle Arbor. The community offers homes starting from the high $200s, featuring single-family floor plans with up to 4 bedrooms and 1,811 sq. ft. Belle Arbor is located near parks, marinas, and employment opportunities in Fort Myers, about 30 miles away. The company’s online homebuying process makes purchasing easier, with quick move-in options and financing through Inspire Home Loans®. -time savings and USDA loan options are available, and the homes come with a new home warranty.",
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.The study highlighted a unique, multimodal mechanism of action and a favorable safety profile. Notably, 44% of the female cancer patients achieved a clinical benefit rate.The company is now moving into Part 3 of the Phase 1 trial, focusing on dose optimization.",
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:00:00.000Z,Low,Neutral,"Bio-Path Holdings (NASDAQ: BPTH) announced that it will present interim data from its Phase 2 clinical trial of prexigebersen for Acute Myeloid Leukemia (AML) at the ASCO Annual Meeting from May 31 - June 4, 2024.The trial, involving prexigebersen combined with decitabine and venetoclax, showed promising results, demonstrating compelling efficacy and good tolerance in newly diagnosed and refractory/relapsed AML patients.This presentation aims to highlight the potential of prexigebersen within the oncology community and encourage broader clinical participation.Details of the presentation include: Title - Interim Safety and Efficacy of BP1001 in a Phase II AML Study, Date - June 1, 2024, Time - 8:00 AM CT, Location - McCormick Place, Abstract Number - 6511.Bio-Path is also advancing other candidates, BP1001-A and BP1002, for various cancers and plans an IND for BP1003 targeting STAT3.",
Community Bancorp. Re-Elects Directors and Discusses Strong 2023 and First Quarter 2024 Results at Annual Shareholders' Meeting,2024-05-23T20:50:00.000Z,No impact,Neutral,"Community Bancorp recently held its Annual Shareholders' meeting, where shareholders re-elected five directors to three-year terms and ratified BerryDunn as the external auditor for 2024.CEO Kathy Austin reported solid financial growth in 2023 and Q1 2024, highlighting a 7% year-over-year increase in total assets, reaching $1.11 billion by March 31, 2024.The bank saw growth in its loan portfolio and deposit base, particularly time deposits, leading to a quarterly dividend raise in 2023. President Christopher Caldwell noted lending growth across all commercial loan segments despite higher interest rates.The bank's strong market position allows for seizing opportunities emerging from industry consolidation. Executive VP and CFO Louise Bonvechio reviewed recent financial results, underscoring the bank's consistent performance and community banking principles.",
Ligand to Participate in Upcoming Investor Conferences,2024-05-23T20:59:00.000Z,Low,Positive,"Ligand Pharmaceuticals (Nasdaq: LGND) announced the participation of its CEO, Todd Davis, and CFO, Tavo Espinoza, in two upcoming investor conferences. The company will attend the Craig-Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, where management will hold one-on-one meetings with investors. Additionally, Ligand will present at the Goldman Sachs Global Healthcare Conference in Miami on June 12, 2024, at 4:00 p.m. ET, and will also be available for one-on-one meetings. Interested investors should contact their respective institutional equity sales representatives at Craig-Hallum or Goldman Sachs.",
Park Aerospace Corp. Announces Date of Fiscal Year Earnings Release and Conference Call,2024-05-23T20:55:00.000Z,Low,Neutral,"Park Aerospace Corp. (NYSE: PKE) plans to release its financial results for the fourth quarter and the full fiscal year ending March 3, 2024, on May 30, 2024, after market close. The company will host a conference call to discuss the results at 5:00 p.m. EDT on the same day.",
Legend Power Systems Reports Q2 F2024 Financial Results,2024-05-23T21:45:00.000Z,Neutral,Neutral,"Legend Power Systems reported its Q2 F2024 financial results, demonstrating an improvement in several key metrics compared to Q2 F2023. The company achieved a revenue increase to $124K from $74K, a 67% rise. The net loss decreased to $907K from $1.19M, and adjusted EBITDA loss improved to $811K from $1.04M. Gross margin turned positive to 46%, compared to the previous negative margin of 7%. Operating expenses dropped by 19% due to effective cost-cutting measures. As of March 31, 2024, Legend Power holds $515K in cash, $1.9M in working capital, and no debt. Operationally, the company has made significant strides with US Federal Government and NYC projects, and continues to build a strong sales pipeline.",
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:15:00.000Z,Low,Neutral,"Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, three-days-off cohort is currently enrolling, with an expansion cohort expected in Q3 2024. Data from 103 patients revealed manageable mild to moderate nausea and vomiting, and less than 10% discontinued due to adverse events. Anti-tumor activity was observed in case studies, and pharmacokinetic modeling predicts increased efficacy at the 80mg dose.",
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting,2024-05-23T21:05:00.000Z,Low,Neutral,"Bicycle Therapeutics (NASDAQ: BCYC) will present emerging Phase 1/2 clinical pharmacokinetic (PK) and safety data for its Bicycle Toxin Conjugates® (BTC®) BT8009 and BT5528 at the 2024 ASCO Annual Meeting. The data show differentiated safety and tolerability profiles compared to antibody drug conjugates (ADCs). The company continues to advance its Phase 2/3 Duravelo-2 trial of BT8009, now named zelenectide pevedotin, for metastatic urothelial cancer, and BT5528 has received FDA Fast Track Designation.Key findings include a shorter half-life for BTC molecules compared to ADCs, leading to rapid tissue penetration and potentially lower toxicities. Adverse events were reported in 84% of patients for zelenectide pevedotin and 91% for BT5528, with fewer severe side effects compared to ADCs. The full clinical data will be presented at ASCO, highlighting the potential of BTC® molecules to improve cancer patient outcomes.",
"BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution",2024-05-23T21:04:00.000Z,No impact,Neutral,"On May 23, 2024, BNY Mellon Alcentra Global Multi-Strategy Credit Fund (XALCX) announced a distribution of $2.00 per share of common stock. This distribution is payable on June 24, 2024, to shareholders recorded by the close of business on June 7, 2024, which is also the ex-dividend date. The Fund aims to maintain quarterly distributions, reflecting its net investment income and broader market conditions. Managed under normal market conditions, the Fund's earnings depend on its asset mix, portfolio maturity, and hedging practices. BNY Mellon Investment Management, a division of BNY Mellon, oversees the Fund, managing $2.0 trillion in assets as of March 31, 2024.",
Tiny Announces Annual General and Special Meeting of Shareholders,2024-05-23T21:23:00.000Z,Neutral,Neutral,"Tiny  (TSXV: TINY) announced its annual general and special meeting of shareholders will be held on June 20, 2024, at the Fairmont Empress in Victoria, B.C.Key matters to be discussed include the approval of consolidated financial statements for the year ending December 31, 2023, setting the number of directors at 5, re-electing current directors Andrew Wilkinson, Chris Sparling, Tim McElvaine, Carla Matheson, and Shane Parrish, re-appointing KPMG LLP as auditors, and ratifying the 10% rolling omnibus equity incentive plan.More details are available in the management information circular on the company's profile page at www.sedarplus.ca and on Tiny's website.",
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101,2024-05-23T21:10:00.000Z,Moderate,Neutral,"Sensei Biotherapeutics has released promising data from the Phase 1 dose escalation study of their human monoclonal antibody, SNS-101, targeting the immune checkpoint VISTA. The study shows that SNS-101 is well-tolerated with no dose-limiting toxicities and demonstrates signs of clinical activity, particularly in tumor types typically unresponsive to PD-1 therapies.Among the 34 patients, promising results were observed in those with microsatellite stable (MSS) endometrial cancer, MSS colorectal cancer, pembrolizumab-resistant renal cell carcinoma, and HPV-positive head and neck cancer.The pharmacokinetic profile of SNS-101 supports once every three-week dosing, showing linear elimination kinetics and dose-proportional increases in exposure. The ongoing dose expansion portion aims to enroll more patients, with initial data anticipated by the end of 2024.",
Limbach Holdings to Participate in Stifel Conference,2024-05-23T22:56:00.000Z,Low,Neutral,"Limbach Holdings announced that its President and CEO, Michael McCann, will participate in the Stifel Cross Sector Insight Conference in Boston. The event is scheduled for June 4-5, where McCann will host one-on-one meetings with investors. Investors interested in meeting him should contact the conference organizers at stifelcorporateevents@stifel.com.",
"Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms",2024-05-23T21:05:00.000Z,Low,Negative,"Bristol Myers Squibb (NYSE: BMY) will present data from over 130 studies on approximately 25 cancer types and blood disorders at the 2024 ASCO and EHA meetings. Highlights include pivotal data on KRAZATI® (adagrasib) for KRASG12C-mutant NSCLC, and CheckMate -9DW trial results on Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for advanced hepatocellular carcinoma. Long-term data for Opdualag™, Opdivo, and Breyanzi® (lisocabtagene maraleucel) will be showcased, highlighting sustained clinical outcomes. Emerging science includes efficacy and safety data for new treatments like the triplet combination of nivolumab, relatlimab, and ipilimumab for advanced melanoma, and the first results of GPRC5D-directed CAR T cell therapy for multiple myeloma. The comprehensive data reflect Bristol Myers Squibb’s commitment to advancing immuno-oncology, targeted therapies, and novel treatment modalities.",
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting,2024-05-23T21:05:00.000Z,Neutral,Neutral,"Corbus Pharmaceuticals (NASDAQ: CRBP) announced that an abstract titled 'Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701)' will be presented at the 2024 ASCO Annual Meeting. This presentation will occur on June 1, 2024, and will provide updated clinical data from a Phase 1 trial. The trial involves dose escalation spanning seven levels and employs a Bayesian Optimal Interval design. The study aims to establish the Maximum Tolerated Dose (MTD) and Phase 2 dose for SYS6002 (CRB-701) in patients with advanced solid tumors unresponsive to standard treatments. Key findings include safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The study is conducted in China by Corbus's partner CSPC, with a parallel Phase 1 study recently initiated in the U.S., where the first patient was dosed in April 2024.",
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting,2024-05-23T21:15:00.000Z,Neutral,Very Positive,"Puma Biotechnology announced the release of abstracts on its drug alisertib, which will be presented at the 2024 ASCO Annual Meeting. The event, scheduled from May 31 to June 4 in Chicago and online, will feature two key studies involving alisertib. The first, Abstract 1037, is a phase II study on alisertib in treating endocrine-resistant metastatic breast cancer, with findings presented by Dr. Karthik Giridhar from Mayo Clinic. The second, Abstract 8572, explores a phase I/Ib study of alisertib combined with osimertinib for osimertinib-resistant EGFR-mutated lung cancer, presented by Dr. Turja Chakrabarti from the University of California, San Francisco. Full abstracts are available online.",
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO,2024-05-23T21:03:00.000Z,Neutral,Neutral,"Regeneron Pharmaceuticals announced promising results from a Phase 1/2 trial of their bispecific antibody REGN7075 combined with Libtayo in advanced solid tumors, particularly microsatellite stable colorectal cancer (MSS CRC). The trial showed a 6% overall response rate (ORR) and 29% disease control rate (DCR) among 51 MSS CRC patients. Positive results were noted, especially in patients without liver metastases. The combination therapy displayed an acceptable safety profile, with no dose-limiting toxicities or treatment-related deaths. Results will be presented at the ASCO 2024 Annual Meeting.",
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement,2024-05-23T21:15:00.000Z,Neutral,Positive,"NW Natural Holdings and NW Natural CEO David H. Anderson announced his retirement, effective April 1, 2025. The Board of Directors named Justin B. Palfreyman, current president of NW Natural Holdings, as Anderson's successor. David has led the company since August 2016, focusing on decarbonization, and building a water, wastewater, and renewables business. The Board expressed confidence in Palfreyman's leadership abilities and strategic vision, citing his strong performance and industry experience. Palfreyman joined NW Natural in 2016 and has held various executive roles, contributing significantly to the company's growth and customer service achievements.",
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma,2024-05-23T21:05:00.000Z,Neutral,Neutral,"IDEAYA Biosciences has released preliminary clinical results from a Phase 2 trial of darovasertib, an oral PKC inhibitor, as a treatment for neoadjuvant uveal melanoma. The study, involving 15 patients, demonstrated a 67% eye preservation rate in patients initially planned for enucleation. Median tumor shrinkage was approximately 39% after six months. Darovasertib was well tolerated, with no serious drug-related adverse events reported. The full data will be presented at the ASCO 2024 Annual Meeting on June 3.",
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting,2024-05-23T21:06:00.000Z,Low,Neutral,"G1 Therapeutics (Nasdaq: GTHX) announced the upcoming presentation of mature Phase 2 results on trilaciclib combined with sacituzumab govitecan (SG) at the ASCO 2024 Meeting from May 31 to June 4 in Chicago. The data indicates a positive impact on overall survival (OS) and tolerability in metastatic triple-negative breast cancer (mTNBC) compared to SG alone. The poster session detailing these findings will occur on June 2, 2024, from 9:00 AM to 12:00 PM CDT.The abstract includes initial trial results shared in January 2024, with the new poster providing updated Phase 2 safety and efficacy outcomes.",
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting,2024-05-23T21:05:00.000Z,Neutral,Neutral,"FibroGen announced positive interim data from a Phase 1b study of FG-3246 (FOR46) in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. Presented at the 2024 ASCO Annual Meeting, the study revealed a median radiographic progression-free survival (rPFS) of 10.2 months in biomarker-unselected patients. FG-3246, an anti-CD46 antibody-drug conjugate, showed an acceptable safety profile with adverse events similar to other MMAE-based therapies. The recommended Phase 2 dose for FG-3246 is set at 2.1 mg/kg every three weeks alongside enzalutamide at 160 mg daily.The trial involved 17 patients, most of whom had received at least two prior androgen receptor signaling inhibitors. The study explored dose escalation with and without granulocyte colony-stimulating factor (G-CSF) support. The primary endpoint was to determine the maximally tolerated dose (MTD) of FG-3246, established at 2.1 mg/kg ABW with primary G-CSF prophylaxis in combination with enzalutamide.",
S&T Bank Begins Lemonade Days Fundraising Campaign To Fight Childhood Cancer,2024-05-23T22:55:00.000Z,Low,Neutral,"S&T Bank, a subsidiary of S&T Bancorp (NASDAQ: STBA), has announced the launch of its second annual Lemonade Days fundraising campaign. Scheduled from June 1 to June 8, 2024, the event will benefit Alex's Lemonade Stand Foundation (ALSF), the largest independent childhood cancer charity in the U.S. During the campaign, visitors to S&T Bank branches can donate to ALSF and receive complementary lemonade and treats. CEO Chris McComish emphasized the bank's commitment to community support, noting that last year's campaign raised over $30,000. This year, the campaign will expand across all S&T Bank markets, aiming to contribute even more to ALSF's mission of funding childhood cancer research and supporting affected families.",
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress,2024-05-23T21:00:00.000Z,Low,Neutral,"Arvinas announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Congress. The event will be held from May 31 to June 4, 2024, in Chicago. The first abstract features initial results from a Phase 1/2 study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer. It will be presented on June 3, 2024, from 1:15 p.m. to 2:45 p.m. CDT under the Genitourinary Cancer category.The second abstract involves TACTIVE-K, a Phase 1b/2 study of vepdegestrant, a PROTAC estrogen receptor degrader, in combination with Pfizer's investigational CDK4 inhibitor, PF-07220060, in ER+/HER2- advanced breast cancer. This will be presented on June 2, 2024, from 9:00 a.m. to 12:00 p.m. CDT in the Breast Cancer—Metastatic category. Abstracts can be accessed on the official ASCO website.",
"Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program",2024-05-23T21:02:00.000Z,Low,Neutral,"Stellar Bancorp announced a quarterly cash dividend of $0.13 per share, payable on June 28, 2024, to shareholders of record as of June 14, 2024. Additionally, the Board of Directors authorized a new share repurchase program allowing the repurchase of up to $60 million of common stock through May 31, 2025. This follows an existing program also permitting $60 million in repurchases through May 31, 2024. Repurchases can be made in various forms, including open market transactions and block trades, depending on factors such as price, market conditions, and corporate priorities.",
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results,2024-05-23T21:10:00.000Z,Neutral,Neutral,"Barnes & Noble Education (NYSE: BNED) has announced its preliminary, unaudited financial results for fiscal year 2024, ending April 27, 2024. The company reported consolidated GAAP revenue of $1.567 billion, a slight increase from $1.543 billion in the prior year. Consolidated GAAP net loss from continuing operations was approximately $63 million, an improvement from the $90 million loss reported last year. Non-GAAP Adjusted EBITDA from continuing operations stood at $45 million, compared to a loss of $8 million the previous year.BNED also announced a proposed series of financial transactions to enhance its financial position, including a fully backstopped $45 million Rights Offering and a $50 million Private Investment led by Immersion  These measures are expected to generate $75 million of net cash proceeds after transaction costs. The company has received commitments to refinance its existing asset-backed loan facility, providing access to a $325 million facility maturing in 2028. Shareholders will vote on these proposals at a special meeting on June 5, 2024.",
"/C O R R E C T I O N -- IDEAYA Biosciences, Inc./",2024-05-23T21:05:00.000Z,No impact,Negative,"IDEAYA Biosciences announced preliminary clinical results from a Phase 2 trial of darovasertib for neoadjuvant treatment in uveal melanoma (UM) at the ASCO 2024 Annual Meeting. The study, led by Dr. Anthony Joshua, involved 15 patients planned for enucleation, treated with darovasertib 300mg twice daily. Results showed a 67% eye preservation rate and a median tumor shrinkage of approximately 45% after six months. The treatment was generally well tolerated, with no serious drug-related adverse events reported. Additional data will be presented on June 3, 2024.",
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting,2024-05-23T21:05:00.000Z,Low,Neutral,"Blueprint Medicines announced updated Phase 1 data for their CDK2 inhibitor, BLU-222, in combination with ribociclib and fulvestrant, for HR+/HER2- breast cancer. The study showed BLU-222 was well-tolerated with no dose-limiting toxicities. Updated data indicate significant biomarker reductions correlated with BLU-222 exposure. Early results suggest clinical activity, including one unconfirmed partial response. Detailed findings will be presented at the 2024 ASCO Annual Meeting.",
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024,2024-05-23T21:05:00.000Z,Moderate,Positive,"I-Mab (NASDAQ: IMAB) announced promising Phase 1 clinical data for its bispecific antibody ragistomig (PD-L1x4-1BB) at the 2024 ASCO Annual Meeting. The data revealed a manageable safety profile and encouraging efficacy in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR). Ragistomig demonstrated an overall response rate (ORR) of 25% at the optimal dose of 5 mg/kg, with a clinical benefit rate (CBR) of 75%. The study included patients with advanced or relapsed/refractory solid tumors, with 71.4% of responders having received prior anti-PD-(L1) therapy. I-Mab highlighted the potential of ragistomig as both monotherapy and in combination with other treatments. The data will be presented by Dr. Gerald Falchook on June 1, 2024, at the ASCO meeting in Chicago.",
Cleantek Industries Inc. Announces First Quarter 2024 Results,2024-05-23T21:00:00.000Z,Low,Positive,"Cleantek Industries announced its first quarter 2024 financial results, reporting revenue of $3,670K, a 4% decrease from Q1 2023. The decline was primarily due to lower HALO fleet utilization, partly offset by HALO lighting unit sales. Despite this, gross profit improved to $2,372K or 65% of revenue, compared to $2,301K or 60% in Q1 2023. Net income rose to $522K, up from $180K. Adjusted EBITDA fell slightly to $1,210K from $1,331K. The company is focusing on expanding its sustainable lighting and wastewater treatment solutions, launching new initiatives like SecureTek and GZeroE, and exploring international markets such as the Middle East.",
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​,2024-05-23T21:01:00.000Z,Moderate,Neutral,"Verastem Oncology (Nasdaq: VSTM) announced positive initial interim safety and efficacy results from its ongoing RAMP 205 Phase 1/2 clinical trial for metastatic pancreatic cancer. The trial evaluates avutometinib plus defactinib combined with gemcitabine and Nab-paclitaxel. As of May 14, 2024, in dose level 1, 83% (5/6) of patients achieved a confirmed partial response. One dose-limiting toxicity was observed but later cleared. The results will be presented at the ASCO Annual Meeting on June 1, 2024. Verastem will host a conference call on May 24, 2024, to discuss these findings.",
Huize Holding Limited Reports First Quarter 2024 Unaudited Financial Results,2024-05-23T22:00:00.000Z,Moderate,Neutral,"Huize Holding  (NASDAQ: HUIZ), a leading insurance technology platform, released its unaudited Q1 2024 financial results, showcasing significant growth and operational efficiency. First Year Premiums (FYP) rose by 29.7% YOY to RMB857.2 million, driven by high-value customer acquisition and product innovation. Operating expenses decreased by 24.9% YOY to RMB81.2 million, improving the expense-to-income ratio to 26.2%. However, Gross Written Premiums (GWP) fell by 11.1% YOY to RMB1,718.0 million, and net profit declined to RMB6.9 million from RMB17.9 million. Despite this, operating revenue increased by 3.8% YOY to RMB310.3 million. Huize's international expansion, particularly in Hong Kong, contributed to its diversified revenue streams. The company remains focused on leveraging AI capabilities and expanding into Southeast Asia.",
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting,2024-05-23T21:00:00.000Z,Low,Positive,"Precigen (Nasdaq: PGEN) will host a webcast on June 3, 2024, at 6:00 PM CT/7:00 PM ET to discuss pivotal study results of PRGN-2012 for treating recurrent respiratory papillomatosis (RRP). The data will be presented earlier that day at 8:30 AM CT during the 2024 ASCO Annual Meeting. This Phase 2 study, led by Dr. Scott M. Norberg, demonstrates that PRGN-2012, a gorilla adenovirus-based immunotherapy, provides complete and durable responses in RRP patients. Participants can register and access the webcast via Precigen's website, and an archived recording will be available post-event. Precigen focuses on gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, leveraging its AdenoVerse platform for advanced gene delivery and therapy development.",
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO),2024-05-23T21:00:00.000Z,Neutral,Positive,"Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotech firm, announced a major update at the ASCO annual meeting on May 23, 2024. They reported on the completion of the first dose cohort in a Phase 1b study of their lead candidate, PH-762. This open-label trial evaluates the safety and tolerability of PH-762 for neoadjuvant use in treating cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. Stages 1 and 2 cSCC, which make up 77% of new cSCC cases annually, have no approved drug treatments. Mary Spellman, MD, the acting Chief Medical Officer, expressed optimism about PH-762's potential to benefit patients while reducing the need for surgery.The presentation, titled 'INTASYL™ PH-762: PD-1 Intratumoral Immunotherapy for Cutaneous Carcinoma,' will be delivered by Mary Spellman, MD, on June 1, 2024, from 1:30 to 4:30 PM CDT.",
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting,2024-05-23T21:01:00.000Z,Moderate,Neutral,"Cogent Biosciences has announced positive updated lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib for treating gastrointestinal stromal tumors (GIST). The combination achieved a median progression-free survival (mPFS) of 19.4 months and a 33% objective response rate (ORR) in a subset of patients. The data will be presented at the ASCO Annual Meeting on June 1, 2024.In addition, Cogent announced a new Phase 2 trial of bezuclastinib plus sunitinib, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC), targeting later-line GIST patients. Enrollment in the PEAK trial is ahead of schedule, now expected to be completed in Q3 2024. The treatment continues to show a favorable safety profile.",
"Sierra Madre Announces Francisco Correa as General Manager of La Guitarra Mine and Mill Complex, Grants Incentive Options",2024-05-23T21:00:00.000Z,Neutral,Very Positive,"Sierra Madre Gold and Silver announced the appointment of Jose Francisco Correa Robles as General Manager of the La Guitarra Silver-Gold Mine and Mill Complex in Estado de Mexico, Mexico. Correa, who has over 23 years of experience in underground mining, has previously worked with Minera Frisco, LuisMin, Genco Resources, Farallon, Silvermex, and First Majestic Silver Corp. He has a strong connection with La Guitarra, having held various roles including General Manager in 2013 and 2015. Additionally, the company has issued stock options to 60 employees, directors, and consultants, granting the purchase of 7,350,000 common shares at $0.50 per share over a five-year period. An additional 225,000 shares were granted to a consultant for a two-year period. These options are subject to acceptance by the TSX Venture Exchange.",
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis,2024-05-23T21:00:00.000Z,Moderate,Neutral,"Eupraxia Pharmaceuticals announced the expansion of its RESOLVE Phase 1b/2a trial for EP-104GI to treat eosinophilic esophagitis (EoE). Encouraging early-phase results with eight of nine patients responding positively and exhibiting good safety profiles spurred this decision. The expansion will allow for higher doses and longer follow-up periods, now up to 52 weeks. The study will include more participants, increasing from 12-15 to 27-33. Additional clinical sites will be established to support the new recruitment targets. The trial aims to gather data to support a potential registration trial in 2025.",
New Research Demonstrates the Importance of Genetic Testing for Many Cancers Not Currently Covered by Clinical Guidelines,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Invitae (OTC:NVTAQ) will present eight studies at the 2024 ASCO Annual Meeting in Chicago from May 31-June 4. The research underscores the importance of genetic testing for various cancers, including gastric, lung, prostate, and breast cancers. Key findings include:- 13.4% of 3,706 gastric cancer patients had pathogenic variants.- 12.6% of 14,317 lung cancer patients had germline variants, independent of smoking history.- Genetic testing in 15,000 prostate cancer patients revealed significant findings even without family cancer history.Studies also emphasize the need for genetic testing in underrepresented populations, with 18.3% of female breast cancer patients in Rwanda having pathogenic variants. Another study found that variants of uncertain significance (VUS) do not lead to overuse of treatment in breast cancer patients.",
"CXApp Inc. (Nasdaq: CXAI) Introduces AI-based Analytics Platform CXAI VU (""SkyView"") in collaboration with Google Cloud",2024-05-23T21:00:00.000Z,Neutral,Neutral,"CXApp unveils its new AI-based analytics platform, CXAI VU ('SkyView'), in collaboration with Google Cloud. Launched on May 23, 2024, this platform aims to enhance workplace efficiency and employee engagement through advanced analytics. CXAI VU offers tailored solutions for HR, facilities, operations, and IT management, emphasizing space optimization, user engagement analytics, data-driven decision-making, and predictive analytics. The platform enables businesses to optimize environments, track app usage, and make data-driven decisions. CXApp's CEO, Khurram Sheikh, and CTO, Naresh Soni, highlight the potential of CXAI VU to revolutionize workplace experiences and promote a new category in enterprise software.",
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress,2024-05-23T21:00:00.000Z,Neutral,Neutral,"Rigel Pharmaceuticals announces significant presentations at the upcoming 2024 ASCO and EHA Hybrid Congresses, showcasing the efficacy of their lead products, REZLIDHIA (olutasidenib) for mIDH1 AML and TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP).The final five-year results from the Phase 2 trial highlight REZLIDHIA's durable responses in heavily pretreated mIDH1 AML patients. Further, REZLIDHIA proves effective in elderly, transplant-eligible, and post-MPN patients.Additionally, data from a Phase 1b trial of R2891, an IRAK1/4 inhibitor for lower-risk myelodysplastic syndrome (LR-MDS), and real-world analyses of TAVALISSE for ITP will be presented.These results underscore Rigel's robust hematology and oncology portfolio, promising significant benefits for patients with challenging conditions.",
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting,2024-05-23T21:01:00.000Z,Low,Neutral,"Zentalis Pharmaceuticals announced the final results of its Phase 1 trial for azenosertib and gemcitabine in relapsed or refractory osteosarcoma patients, revealing a substantial improvement in event-free survival (EFS). The trial demonstrated a tripling of EFS at 18 weeks compared to historical data. Azenosertib was well tolerated, with thrombocytopenia and lymphopenia being the most common severe adverse events. The maximum tolerated dose was identified as 150 mg of azenosertib daily on a 5:2 schedule plus 800 mg/m2 of gemcitabine. The results support further investigation in a Phase 2 trial. The full data will be presented at the 2024 ASCO Annual Meeting.",
"Greenfire Resources Announces Participation in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024",2024-05-23T21:29:00.000Z,Neutral,Neutral,"Greenfire Resources (NYSE: GFR, TSX: GFR), a Calgary-based energy company, will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company will give a webcast presentation at 1:15pm ET and conduct one-on-one meetings with investors. The webcast can be accessed on the conference homepage or Greenfire's website and will be available for replay post-event. For one-on-one meetings, interested parties can contact Lytham Partners or register on the event website.",
"PARAMOUNT GLOBAL AND CHARTER COMMUNICATIONS ANNOUNCE NEW MULTI-YEAR AGREEMENT FOR DISTRIBUTION OF PARAMOUNT'S LINEAR NETWORKS, CBS OWNED-AND-OPERATED STATIONS AND DIRECT-TO-CONSUMER STREAMING SERVICES",2024-05-23T21:15:00.000Z,Neutral,Very Positive,"Paramount Global and Charter Communications announced a new multi-year distribution agreement to extend their partnership.This deal will allow Paramount's linear cable networks, CBS stations, and streaming services to continue being available on Charter's Spectrum packages. Popular channels like BET, Comedy Central, MTV, and Nickelodeon will remain accessible, along with Paramount+ with Showtime.The ad-supported versions of Paramount+ Essential and BET+ Essential will be added at no extra cost to Spectrum subscribers. Internet-only customers can purchase Paramount's streaming services through Charter.Charter will benefit from revenue shares on new subscriptions and ad-free upgrades. Financial terms of the deal were not disclosed.",
CXApp Inc. (Nasdaq: CXAI) Announces Record NRR Growth for Q1’24 & Launch of CXAI VU in collaboration with Google Cloud,2024-05-23T21:01:00.000Z,Moderate,Neutral,"CXApp (NASDAQ:CXAI) reported a record Net Retention Rate (NRR) of 108% in Q1 2024, largely due to renewals and expansions by seven Fortune 1000 clients across five sectors. The company also launched its AI-based Analytics Platform, CXAI VU, in collaboration with Google Cloud, aiming to transform workplace efficiency and employee engagement. Financially, CXApp achieved a gross margin of 82%, with subscription-based revenue comprising 87% of total revenue, marking a 6-point increase from the previous quarter. Additionally, operational costs were reduced by 20% compared to Q4 2023.",
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:30:00.000Z,Neutral,Neutral,"Aadi Bioscience presented new nonclinical data at the ASCO Annual Meeting showing that nab-sirolimus achieved higher intratumoral drug concentrations, stronger mTOR target inhibition, and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model. These findings support further clinical studies of nab-sirolimus, either alone or in combination therapies. The data will be published in the Journal of Clinical Oncology. Aadi will also present a poster on a Phase 2 trial of nab-sirolimus plus letrozole in advanced or recurrent endometrioid-type endometrial cancer. This trial aims to evaluate the efficacy and safety of the combination, exploring its potential to offer additive anti-tumor activity for EEC patients. Endometrial cancer is a significant focus due to its rising mortality rates, and Aadi's study aims to address the unmet needs in this difficult-to-treat cancer type.",
Deveron Announces Dates for Q3 2024 Earnings Release,2024-05-23T21:15:00.000Z,Neutral,Neutral,"Deveron Corp., a prominent agriculture service and data company in North America, announced it will release its Q3 2024 financial results after market close on Tuesday, May 28, 2024. The results will be posted on SEDAR Plus and Deveron's financials web page. A live audio webcast to discuss these results will be held on Wednesday, May 29, 2024, at 8:00 AM Eastern Time. Participants can access the webcast through a specific link or by dialing in. A transcript and audio replay will be available on Deveron's Investor website after the event.",
American Aires Extends Global Expansion by Opening Latest International Fulfillment Center in the UK,2024-05-23T21:15:00.000Z,Low,Neutral,"American Aires announced the opening of a new international fulfillment center in Bardon Hill, UK. This move is part of their strategy to expand globally and improve customer service. The company recently reported a record annual order volume of $10.4 million for 2023, a 79% increase YoY. The new UK center will help Aires streamline logistics, offer faster fulfillment times, and improve local marketing ahead of the holiday season. The company anticipates that the new center will enhance sales conversions, replicating the success seen in other regions like Australia and Europe.The UK center is strategically placed to leverage similarities in market dynamics with the US, Canada, and Australia. Aires' CEO, Josh Bruni, emphasized the importance of this expansion in boosting the company’s presence in the UK, which currently represents only 2% of its global order volumes. The center is expected to enhance customer trust and reduce customs-related delays, aiming for significant growth over the next 12-24 months.",
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,2024-05-23T21:13:00.000Z,Neutral,Neutral,"SpringWorks Therapeutics will present four abstracts at the 2024 ASCO Annual Meeting from May 31 to June 4, 2024. Key highlights include data from the Phase 2b ReNeu trial of mirdametinib for NF1-PN patients, showing significant tumor volume reductions and improved quality of life for both adults and children. Additionally, three analyses from the Phase 3 DeFi trial of nirogacestat for desmoid tumors will be presented, demonstrating consistent safety and efficacy. The ReNeu trial reported a 41% confirmed ORR in adults and 52% in children, with deep and durable tumor volume reductions. In the DeFi trial, nirogacestat showed improvements in progression-free survival and overall response rate in high-risk desmoid tumor patients.",
Elcora Announces Share Consolidation,2024-05-23T21:05:00.000Z,High,Neutral,"Elcora Advanced Materials Corp. (TSX.V: ERA | Frankfurt: ELM | OTCQB – ECORF) announced a 10-to-1 share consolidation. This move, pending TSX Venture Exchange approval, will reduce the number of outstanding shares from 170,377,013 to approximately 17,037,701. No fractional shares will be issued, with all fractions rounded down. Share prices and convertible securities will adjust proportionately. The company aims to attract more financing opportunities with this consolidation. There will be no changes to the company's name or trading symbol. Further details will be released at a later date.",
"Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting",2024-05-23T21:51:00.000Z,Moderate,Neutral,"Coherus BioSciences announced preliminary Phase 1 results for CHS-114, an anti-CCR8 antibody, at the 2024 ASCO Annual Meeting. CHS-114 exhibited an acceptable safety profile with no dose-limiting toxicities in heavily pretreated patients with solid tumors. Selective depletion of CCR8+ Tregs was maintained, establishing proof of mechanism. One patient experienced Grade 2 colitis as a serious adverse event. Pharmacokinetic data showed dose proportional exposure and a linear elimination half-life of about 10 days. The results support further evaluation of CHS-114 in combination with toripalimab and other immuno-oncology agents. No objective responses were noted, but a stable disease rate of 47% was observed in 19 evaluable patients.",
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer,2024-05-23T21:05:00.000Z,Low,Neutral,"Cogent Biosciences has named Cole Pinnow as Chief Commercial Officer, effective May 23, 2024. Pinnow brings 25 years of biopharmaceutical industry experience, including roles at Pfizer where he led a $5B cancer portfolio. At Cogent, Pinnow will oversee the commercial strategy for the anticipated launch of bezuclastinib, aimed at treating systemic mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST).His appointment includes inducement equity awards of 525,000 stock options and up to 214,000 performance-based restricted stock units, encouraging long-term company growth. CEO Andrew Robbins highlighted Pinnow's expertise as important for transitioning Cogent into a fully integrated commercial organization.",
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024,2024-05-23T21:05:00.000Z,Neutral,Neutral,"Affimed has announced promising early results from its AFM24-102 study involving 15 evaluable patients with metastatic EGFR wild-type non-small cell lung cancer (NSCLC). These patients, pretreated with platinum doublet chemotherapy and checkpoint inhibitors, received a combination of AFM24 and atezolizumab, resulting in a disease control rate (DCR) of 73.3%. This included one complete response and three partial responses, with a median progression-free survival of 5.9 months. The study's data cut-off was March 18, 2024. These findings will be presented at the ASCO annual meeting on June 1, 2024. Affimed will also host a conference call/webcast the same day to discuss these results and other clinical data.",
"Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024",2024-05-23T21:04:00.000Z,Low,Neutral,"Cullinan Therapeutics announced preliminary data from its Phase 1 trial of CLN-619, an anti-MICA/B antibody, in combination with pembrolizumab, and updated monotherapy results. Among 22 patients treated with the combination, 3 showed partial responses, including in non-small cell lung cancer (NSCLC) and gastric cancer. Monotherapy results showed a 41.4% clinical benefit rate across various tumor types. CLN-619 was well tolerated, with most adverse events being mild. Cullinan is expanding the trial to include more NSCLC patients and has plans for further studies in multiple myeloma.",
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting,2024-05-23T21:01:00.000Z,Moderate,Neutral,"HOOKIPA Pharma announced positive results from its Phase 1/2 trial of HB-200 for HPV16+ head and neck cancers, to be presented at ASCO 2024. The study, which involved 42 patients, showed an objective response rate (ORR) of 53% and a disease control rate (DCR) of 82% among patients with PD-L1 CPS of 20 or higher. HB-200 combined with pembrolizumab exhibited a favorable safety profile, with no treatment-related deaths and low treatment discontinuation rates. Additional data, including preliminary progression-free survival and overall survival, will be presented on June 4, 2024. Preliminary findings from an investigator-initiated trial for HB-200 with chemotherapy in non-metastatic HPV16+ cancers showed promising results, with an 81% deep response rate. Preclinical data for HB-700, targeting KRAS mutations, demonstrated effective T-cell responses and tumor cell killing in mice.",
Acme United Corporation Acquires the Assets of Elite First Aid,2024-05-23T20:46:00.000Z,Neutral,Negative,"Acme United  (ACU) has acquired the assets of Elite First Aid, a supplier of tactical, trauma, and emergency response products with 2023 revenues of $4.2 million. The undisclosed purchase price is expected to be accretive. Located in Wake Forest, NC, Elite First Aid will join Acme United's portfolio, expanding its emergency response product sales to domestic and global markets. The founder and management team of Elite First Aid will join Acme United, alongside its employees.",
Philips successfully prices offering of Notes for EUR 700 million to be used for repayment of existing debt,2024-05-23T20:30:00.000Z,Neutral,Neutral,"Royal Philips has successfully priced its offering of EUR 700 million fixed rate notes, set to mature in 2032, under its European Medium Term Note (EMTN) program. The notes were priced at 98.257% with a 3.75% coupon, resulting in a yield of 4.009%. The issue, which was over two times oversubscribed, aims to be debt-neutral as it will be used to repay existing debt due in 2024 and 2025. Philips holds a BBB+ rating from Standard & Poor's and Fitch, and a Baa1 rating from Moody's. The settlement and issue of the notes are scheduled for May 31, 2024, and the notes will be listed on the Luxembourg Stock Exchange. This offering is not registered under the U.S. Securities Act and is not intended for retail investors in the EEA or UK.",
HUB Security Provides an Update on the 2023 Annual Report,2024-05-23T20:36:00.000Z,Neutral,Neutral,"HUB Cyber Security announced they need more time to complete the audit of their annual financial statements and file their Annual Report for the fiscal year ended December 31, 2023. This delay is due to the recent acquisition of QPoint and efforts to finalize debt restructuring. HUB received a notice from Nasdaq indicating non-compliance with listing rules but this does not affect their current listing or trading. HUB has until July 19, 2024, to submit a compliance plan and may receive an extension until November 11, 2024, if Nasdaq approves. HUB remains optimistic about meeting these requirements.",
NioCorp Engages J.P. Morgan to Assist with EXIM Financing of Elk Creek Critical Minerals Project,2024-05-23T20:35:00.000Z,Neutral,Neutral,"NioCorp Developments has engaged J.P. Morgan to assist in securing debt financing from the Export-Import Bank of the U.S. (EXIM) for its Elk Creek Critical Minerals Project. Having progressed through the first of EXIM's three Transaction Review Committee reviews, NioCorp received a preliminary indicative term sheet in April 2024. However, final loan approval from EXIM's Board of Directors is still pending. The collaboration aims to accelerate the financing and construction start of the project.",
"Our People: Lora Collins, Woman of Asphalt",2024-05-23T20:45:00.000Z,Low,Neutral,"Lora Collins, Asphalt Value Chain Senior Director for Marathon Petroleum, has been appointed to the board of Women of Asphalt. This is a coalition aimed at inspiring women in the asphalt industry. Collins, a science enthusiast with a B.S. in Chemistry from Ohio Northern University, has had a notable career trajectory. Starting at Pfizer and Procter & Gamble in research roles, she transitioned to Marathon Petroleum in 2007. There, she climbed the ranks through various marketing and management positions before taking on her current role. Marathon Petroleum, the largest asphalt producer in the U.S., markets over 130 asphalt products from seven refineries and operates a comprehensive asphalt system with 27 terminals nationwide. Collins is passionate about advancing asphalt technology and the role of women in the industry, serving on the boards of both the Women of Asphalt and the Asphalt Institute, and chairing the Asphalt Institute Foundation.",
Genworth Financial Announces Results of Annual Meeting,2024-05-23T20:40:00.000Z,Low,Neutral,"Genworth Financial (NYSE: GNW) announced the results of its 2024 annual meeting of stockholders. All nine director nominees were re-elected, including G. Kent Conrad and Karen E. Dyson. Stockholders also approved executive officer compensation and ratified KPMG LLP as the independent accounting firm for 2024. Additionally, stockholders passed an Amended and Restated Certificate of Incorporation, removing references to legacy GE provisions and granting stockholders the right to request a special meeting at a 25% ownership threshold. These changes will take effect early next month.",
SEE Declares Quarterly Cash Dividend,2024-05-23T20:30:00.000Z,Low,Neutral,"SEE (NYSE: SEE) has announced a quarterly cash dividend of $0.20 per common share. This dividend is payable on June 28, 2024, to stockholders recorded as of June 14, 2024.",
Chemours Washington Works Awards Five Local Students With Scholarships,2024-05-23T20:45:00.000Z,Low,Very Positive,"Chemours' Washington Works site has awarded scholarships to five local students as part of its Future of Chemistry Scholarship program. These scholarships aim to support students pursuing STEM (Science, Technology, Engineering, Mathematics) education. The initiative is part of Chemours' broader commitment to invest $50 million in safety, sustainability, and STEM education programs by 2030. The scholarships range from $7,000 to $10,000 per year and are renewable. The recipients will attend either West Virginia University - Parkersburg or Ohio University. Chemours also collaborates with local schools and organizations to promote STEM education and offers Co-Op opportunities for college students.",
"Penumbra, Inc. to Present at the William Blair Growth Stock Conference",2024-05-23T20:30:00.000Z,Low,Neutral,"Penumbra announced that its management team will present at the William Blair Growth Stock Conference on June 6, 2024, at 12:20pm ET/9:20am PT. The event will be webcast live and accessible through the company's website under the 'Investors' tab, where it will remain available for two weeks after the presentation.",
StageZero Life Sciences Announces Update on Failure to File Cease Trade Order,2024-05-23T20:30:00.000Z,Moderate,Neutral,"StageZero Life Sciences announced that it remains under a Failure to File Cease Trade Order (FFCTO) due to a delay in filing its 2023 year-end financials. The company cited insufficient financial resources to pay auditors as the cause of the delay. The Ontario Securities Commission has granted StageZero 90 days to rectify the situation, giving them a deadline of July 3, 2024. Despite efforts to file ahead of the deadline, StageZero will not meet the originally referenced May 31, 2024, filing date. The FFCTO prohibits any trading of the company's securities in Canada until the filings are completed and the order is revoked. StageZero confirms no other undisclosed material information about its affairs.",
"Pyxus International, Inc. Announces Fourth Quarter and Full Year Fiscal Year 2024 Financial Results Earnings Call",2024-05-23T20:30:00.000Z,Moderate,Neutral,"Pyxus International, a global agricultural company, has announced the release of its fourth quarter and fiscal year 2024 financial results. The report will be made public on June 6, 2024, with an earnings call scheduled for 9 a.m. ET the same day. Investors and analysts can join via a dedicated phone line or webcast. The financial results and a presentation will be available on the company's investor relations webpage. Pyxus emphasizes its commitment to responsible sourcing and sustainability in its operations.",
Tanger Schedules Second Quarter 2024 Earnings Release and Conference Call,2024-05-23T20:37:00.000Z,Low,Neutral,"Tanger (NYSE: SKT) announced it will release its financial results for the second quarter of 2024 on August 1, 2024, after market close. A conference call for analysts, investors, and other interested parties will be held on August 2, 2024, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-605-1702, and a live audio webcast will be available on Tanger's Investor Relations website. A telephone replay will be accessible from August 2 to August 16, 2024, by dialing 1-877-660-6853, replay access code #13746825. An online archive of the webcast will also be available through August 16, 2024.",
Greenlane Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1),2024-05-23T20:30:00.000Z,Low,Neutral,"Greenlane Holdings (NASDAQ: GNLN) announced that on May 21, 2024, it received a Nasdaq notification of non-compliance with Listing Rule 5250(c)(1) due to its failure to timely file its Quarterly Report on Form 10-Q for Q1 2024.The company had previously received a similar notice on April 18, 2024, for not filing its Annual Report on Form 10-K for FY 2023. Greenlane has until June 17, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may grant up to an additional 180 days to meet the requirements. Failure to comply could result in delisting.Greenlane is working to submit the necessary filings as soon as possible. However, there is no assurance that the filings will be made within the 60-day window.",
THOR Industries Announces Date For Its Fiscal 2024 Third Quarter Earnings Release,2024-05-23T20:49:00.000Z,Low,Neutral,"THOR Industries (NYSE: THO) has announced the release date for its fiscal 2024 third quarter earnings on Wednesday, June 5, 2024, before the market opens. Alongside the earnings report, THOR will publish a comprehensive question and answer document and a slide presentation on its website. Investors and interested parties can access these documents at http://ir.thorindustries.com/.",
"Newtopia Reports Fourth Quarter, Full Year 2023 and First Quarter 2024 Financial Results",2024-05-23T20:30:00.000Z,Neutral,Neutral,"Newtopia has reported its Q4 2023, full year 2023, and Q1 2024 financial results. The company saw a decrease in revenue across all periods due to changes in a major client's incentive program. Q4 2023 revenue was $2.3M, down 25% YoY; full year 2023 revenue was $9.8M, down 12% YoY; and Q1 2024 revenue was $1.8M, down 31% YoY. Gross profit margins were 63%, 62%, and 50% for Q4 2023, full year 2023, and Q1 2024, respectively. Net cash stood at $0.4M at the end of Q4 2023 and $0.33M at the end of Q1 2024. The company has reduced operating expenses significantly. Newtopia is optimistic about growth opportunities with GLP-1 drugs and health AI partnerships.",
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 24,2024-05-24T06:00:00.000Z,No impact,Neutral,"InterContinental Hotels Group (IHG) announced the repurchase of 36,078 ordinary shares on May 23, 2024, through Goldman Sachs International, as part of a shareholder-approved buyback plan. The shares were bought at prices ranging from £78.70 to £79.50, with an average price of £79.059 per share. Post-transaction, IHG's total shares in issue stand at 162,270,185, excluding 7,006,782 treasury shares. The repurchased shares will be canceled, reducing the company's share count and potentially increasing shareholder value. This move follows a February 20, 2024, directive, reaffirmed at the May 3, 2024, Annual General Meeting.",
Bloom Energy Corporation Prices Upsized $350.0 Million Green Convertible Senior Notes Offering,2024-05-24T05:11:00.000Z,Neutral,Neutral,"Bloom Energy  (NYSE: BE) has announced the pricing of its upsized $350 million Green Convertible Senior Notes offering. The notes, set to mature in 2029, carry a 3.00% annual interest rate and are convertible into Class A common stock under certain conditions. The initial conversion price is approximately $20.84 per share, a 32.5% premium over the current share price. The offering size was increased from the previously announced $250 million. Settlement is expected on May 29, 2024. Net proceeds are estimated at $338.8 million, with $141.8 million allocated to repurchase outstanding 2025 notes and the rest for corporate purposes. The notes are redeemable under specific conditions and provide rights for repurchase by noteholders in case of a fundamental change.",
,,,,,
On Elects Laura Miele as a New Independent Member of the Board of Directors,2024-05-23T20:30:00.000Z,Low,Very Positive,"Swiss performance sportswear brand On (NYSE: ONON) has elected Laura Miele as an independent member of its Board of Directors and a member of its Audit Committee. Miele brings substantial experience from Electronic Arts (EA), where she is President of EA Entertainment & Technology. Her expertise includes digital transformation, expanding consumer demographics, and managing international teams. On’s Co-Founder, Caspar Coppetti, expressed confidence in Miele’s ability to contribute to the Board’s expertise. Miele also expressed enthusiasm about supporting On’s next growth phase. The Board confirms that Miele meets all independence and financial literacy requirements set by the SEC and NYSE.",
Lincoln National Corporation';s Board of Directors Declares Quarterly Cash Dividend,2024-05-23T20:30:00.000Z,Low,Neutral,"Lincoln Financial Group (NYSE: LNC) has announced that its board of directors has declared a quarterly cash dividend of $0.45 per share on the ’s common stock. This dividend will be payable on August 1, 2024, to shareholders of record as of the close of business on July 10, 2024.",
Hecla Announces Leadership Transition,2024-05-23T20:30:00.000Z,Low,Neutral,"Hecla Mining Company (NYSE: HL) has announced a leadership transition with Catherine J. “Cassie” Boggs appointed as the Interim President and CEO. Ms. Boggs, currently the Chair of the Board, succeeds Phillips S. Baker Jr., who is retiring after nearly 23 years of service. In addition to her new role, she will continue as Chair of the Board, and Charles B. Stanley will serve as Lead Independent Director starting May 23, 2024. Ms. Boggs will be supported by a committee of senior executives. The Board has initiated a search for a permanent CEO.Ms. Boggs brings over 40 years of mining industry experience, including roles at Resource Capital Funds, Barrick Gold , and Tethyan Copper Company. The company assures that day-to-day operations will remain unaffected during the transition.",
Caleres Declares Regular Quarterly Dividend,2024-05-23T20:30:00.000Z,Low,Neutral,"Caleres (NYSE: CAL), a leading portfolio of consumer-driven footwear brands, has declared a regular quarterly cash dividend of $0.07 per share. The dividend will be paid on June 20, 2024, to shareholders of record as of June 5, 2024. This announcement marks the continuation of a tradition, as the company has consistently paid a quarterly dividend for over 100 years.",
"Secret Creek Fish Passage Project Nets Granite $48 Million Contract in Snohomish County, Washington",2024-05-23T20:30:00.000Z,Neutral,Neutral,"Granite (NYSE:GVA) has secured a $48 million contract from the Washington State Department of Transportation (WSDOT) to replace two fish barrier culvert crossings with three new fish passable structures on I-5 in Snohomish County, Washington. This project, funded by WSDOT, will be part of Granite's second-quarter CAP and builds on their successful Padden Creek project completed in 2022. Granite will import 95,000 tons of gravel from its Conway Aggregate Facility for the project, which aims to support WSDOT's compliance with a 2030 injunction. The project is set to start in June 2024 and expected to complete by December 2026.",
Enhabit Provides Additional Details on Robust Strategic Review Process,2024-05-23T20:30:00.000Z,Moderate,Neutral,"Enhabit (NYSE: EHAB) filed its preliminary proxy materials with the SEC for its 2024 annual meeting. This step follows a nine-month strategic review process, influenced by AREX Capital Management's push for the company’s sale. Despite efforts involving 38 potential counterparties, no formal offers were received. Challenges included regulatory changes, high interest rates, and the healthcare operating environment. The Board engaged fully in the review but decided to terminate the process without actionable proposals.",
Alerus Financial Corporation Declares Cash Dividend on Common Shares,2024-05-23T20:30:00.000Z,Low,Neutral,"Alerus Financial  (NASDAQ: ALRS) has announced a regular quarterly cash dividend of $0.20 per common share. This marks a 5.26% increase over the dividend paid in the previous year. The dividend will be payable on July 15, 2024, to shareholders of record as of June 14, 2024. This decision highlights the company's commitment to returning value to its shareholders. For more information, including historical dividend data and financial performance, investors can visit the Alerus investor relations website.",
Interpublic Declares Common Stock Dividend,2024-05-23T20:30:00.000Z,Low,Neutral,"Interpublic Group (NYSE: IPG) announced that its Board of Directors has declared a quarterly dividend of $0.33 per share on its common stock. The dividend will be payable on June 18, 2024, to shareholders of record as of June 4, 2024. This announcement reflects the company's commitment to returning value to its shareholders. In 2023, Interpublic reported total revenue of $10.89 billion. The company is known for its innovative marketing solutions through global brands like Acxiom, FCB, IPG Mediabrands, and more.",
Quanex Building Products Declares Quarterly Dividend,2024-05-23T20:16:00.000Z,Low,Neutral,"Quanex Building Products (NYSE:NX) has declared a quarterly cash dividend of $0.08 per share on its common stock. The dividend will be paid on June 28, 2024, to shareholders who are recorded as of June 14, 2024.",
Genco Shipping & Trading Shareholders Overwhelmingly Re-Elect All Genco Director Nominees at the 2024 Annual Meeting,2024-05-23T20:15:00.000Z,Neutral,Neutral,"Genco Shipping & Trading (NYSE: GNK), a leading U.S.-based drybulk shipowner, announced that shareholders have re-elected all seven of its director nominees at the 2024 Annual Meeting. The re-election process saw approximately 61.4% of the company's total shares represented, with over 85% of votes cast in favor of the nominees. Similarly, the 'say-on-pay' resolution and the appointment of Deloitte & Touche LLP as auditors were approved by a large margin. The company views these results as a strong endorsement of its Board, management team, and Comprehensive Value Strategy. Genco is committed to maintaining robust corporate governance and aims to deliver sustainable shareholder value amidst volatile market cycles.",
"Stonegate Initiates Coverage on BlackSky Technology, Inc. (BKSY)",2024-05-23T20:28:00.000Z,Neutral,Neutral,"Stonegate Capital Partners has initiated coverage on BlackSky Technology (NYSE: BKSY) as of May 23, 2024. The key highlights include a 31.7% year-over-year increase in revenue and the securing of $30 million in new contract and renewal agreements. Additionally, BlackSky's Gen 3 satellites are scheduled to start launching in fiscal year 2024.",
Belden Declares Quarterly Dividend,2024-05-23T20:15:00.000Z,Low,Neutral,"Belden (NYSE: BDC) has announced a quarterly dividend of $0.05 per share.This dividend is payable on July 9, 2024, to shareholders who are recorded by June 13, 2024.",
Dolby Laboratories to Present at Upcoming Investor Conferences,2024-05-23T20:15:00.000Z,Low,Neutral,"Dolby Laboratories (NYSE: DLB) announced that its management will present at two upcoming investor conferences. CEO Kevin Yeaman will present at the William Blair Growth Stock Conference in Chicago on June 4, 2024, at 10:00 AM CT (11:00 AM ET). In addition, Peter Goldmacher, VP of Investor Relations, will participate in a fireside chat at the Baird Global Consumer, Technology & Services Conference in New York on June 5, 2024, at 10:50 AM ET. Both events will be available via live webcast and replay at the Dolby investor relations website.",
"Dime Hires Judy Wu as Executive Vice President, General Counsel and Corporate Secretary",2024-05-23T20:30:00.000Z,Low,Neutral,"Dime Community Bancshares has appointed Judy Wu as Executive Vice President, General Counsel, and Corporate Secretary. Wu brings extensive experience from her previous roles at Flagstar Bank and Signature Bank, where she specialized in regulatory compliance and privacy. Dime's President and CEO, Stuart H. Lubow, expressed confidence in Wu's ability to contribute to the company's growth strategy. Wu holds a bachelor's degree in finance and accounting from NYU and a law degree from Fordham University School of Law.",
Stevanato Group to Present at Upcoming Investor Conferences,2024-05-23T20:30:00.000Z,Low,Neutral,"Stevanato Group (NYSE: STVN), a leading global provider of drug containment, delivery, and diagnostic solutions, will participate in two upcoming investor conferences. These events are the William Blair Growth Stock Conference in Chicago on June 4, 2024, at 4:00 p.m. (CT), and the Jefferies Healthcare Conference in New York City on June 6, 2024, at 9:30 a.m. (ET). Live webcasts will be available on the Stevanato Group's website under the 'Investors' section, with replays accessible for approximately 90 days post-event.",
SiriusPoint Announces Jim McKinney as Chief Financial Officer,2024-05-23T20:15:00.000Z,Low,Very Positive,"SiriusPoint, a global specialty insurer and reinsurer (NYSE: SPNT), has appointed Jim McKinney as Chief Financial Officer, effective June 3, 2024. McKinney brings over 20 years of experience, having previously served as CFO at Kemper  and Banc of California. He has a track record of creating high-performing finance functions and leading transformations for growth. McKinney will report to CEO Scott Egan and join SiriusPoint's Executive Leadership Team. The current CFO, Steve Yendall, will be succeeded by McKinney and leaves with the company's best wishes.",
Cadence’s Anirudh Devgan to Present at Bernstein Conference,2024-05-23T20:15:00.000Z,Low,Neutral,"Anirudh Devgan, CEO of Cadence Design Systems (Nasdaq: CDNS), will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on May 30, 2024. His presentation will be webcast live at 8:00 a.m. PDT and archived on the Cadence website for 90 days. Interested parties can access the webcast and replay it at cadence.com/cadence/investor_relations.",
"ProAssurance Announces Election of Richard J. Bielen, C.P.A., and Staci M. Pierce, J.D., to Board",2024-05-23T20:20:00.000Z,Low,Neutral,"ProAssurance announced the election of Richard J. Bielen, CPA, and Staci M. Pierce, JD, to its Board of Directors at the Annual Meeting of Shareholders on May 22. Additionally, Bruce D. Angiolillo, JD, and Samuel A. Di Piazza, Jr., CPA, were re-elected for three-year terms. The board now has 10 members, down from 12.Shareholders also approved the 2024 Equity Incentive Plan and ratified Ernst & Young, LLP as the independent auditor for fiscal year 2024. Compensation for named executive officers was approved on an advisory basis. All proposals received substantial support.Bielen, CEO of Protective Life , brings over 35 years of financial services experience, while Pierce, CEO of Action Resources, has eight years in executive roles in transportation and environmental services industries and five years as an attorney.",
Millicom (Tigo) comments on shareholder communication,2024-05-23T20:30:00.000Z,Neutral,Neutral,"Millicom (Tigo) has received a non-binding expression of interest from shareholder Atlas Luxco S.à.r.l. regarding a potential all-cash tender offer for all outstanding shares at $24 per share. This follows Atlas's earlier press release and Form 13D filing. The Board of Directors will review any forthcoming offer, but there is no certainty of a transaction occurring, nor clarity on its terms, timing, or form.",
Sallie Mae CFO to Speak at TD Financial Services & Fintech Summit,2024-05-23T20:30:00.000Z,Low,Neutral,"Sallie Mae (Nasdaq: SLM) announced that its Chief Financial Officer, Pete Graham, will speak at the TD Financial Services & Fintech Summit on Thursday, June 6, at 10:55 a.m. ET. The event will feature a live audio webcast and a replay available on SallieMae.com/investors. Sallie Mae, a leader in private student lending, emphasizes the importance of education and lifelong learning in achieving significant milestones. The company offers financing and resources to support college access and post-college goals. For more details, visit SallieMae.com.",
Kimberly-Clark to Webcast its Presentation at Bernstein's 40th Annual Strategic Decisions Conference,2024-05-23T20:15:00.000Z,Low,Neutral,"Kimberly-Clark Chairman and CEO, Mike Hsu, will speak at Bernstein's 40th Annual Strategic Decisions Conference on May 30, 2024, at 9 am ET. The presentation will be webcast, accessible through the Investors section of Kimberly-Clark's website.",
SoCalGas Receives Organizational Leadership Award from The Climate Registry for its ASPIRE 2045 Sustainability Strategy,2024-05-23T20:15:00.000Z,No impact,Neutral,"Southern California Gas Company (SoCalGas) has received the 'Organizational Leadership Award' from The Climate Registry at the Climate Leadership Conference for its ASPIRE 2045 sustainability strategy. This award recognizes SoCalGas' leadership in reducing greenhouse gas (GHG) emissions and addressing climate change. The company's initiatives include surpassing California's goal by reducing fugitive and vented methane emissions by 20% from a 2015 baseline by 2025, converting 38% of its fleet vehicles to alternative fuels, and aiming for a 100% zero emissions vehicle fleet by 2035. SoCalGas has also delivered 5% renewable natural gas to core customers in 2023, with a goal of 20% by 2030. SoCalGas has also received the 'Business Transformation Award' from Reuters Events and has been recognized for its clean hydrogen microgrid project.",
"BELLEVUE CAPITAL PARTNERS, LLC INCREASES THE PURCHASE PRICE FOR ITS PREVIOUSLY ANNOUNCED TENDER OFFER FOR SHARES OF AMERICAN STRATEGIC INVESTMENT CORP.",2024-05-23T20:15:00.000Z,Neutral,Neutral,"Bellevue Capital Partners has increased its tender offer price for American Strategic Investment Corp. (NYSE: NYC) shares from $9.25 to $10.25 per share. This new offer represents a 77% premium over ASIC's closing price on May 3, 2024. The tender offer aims to purchase up to 125,000 shares and will close on July 5, 2024. Investors can withdraw tenders before the expiration date.",
WisdomTree Publishes Presentation Highlighting Company’s Track Record of Success and Strategic Momentum Ahead of 2024 Annual Meeting of Stockholders,2024-05-23T20:15:00.000Z,Neutral,Positive,"WisdomTree has released a comprehensive presentation ahead of its 2024 Annual Meeting of Stockholders, scheduled for June 12, 2024, to highlight its financial performance and strategic achievements.Key points include record assets under management (AUM), continuous organic growth, and margin expansion. The company boasts a near 40% year-to-date stock price increase due to strong financial results. WisdomTree's strategy includes investments in tokenization and blockchain-enabled finance.The presentation also emphasizes the importance of a refreshed Board, with 67% female representation. WisdomTree urges stockholders to vote 'FOR' all its director nominees and reject ETFS Capital's demands for a strategic review, which WisdomTree claims are self-serving and against long-term shareholder interests.",
"Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences",2024-05-23T20:15:00.000Z,Low,Negative,"Inotiv (Nasdaq: NOTV) announced participation in the 21st Annual Craig Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, and the Jefferies Global Healthcare Conference in New York from June 4-6, 2024. Key executives, including CEO Robert Leasure Jr. and CFO Beth Taylor, will engage in one-on-one meetings and presentations aimed at institutional investors, with a notable presentation at 10:30 AM ET on June 6, 2024. Investors can schedule meetings via their sales reps at Craig Hallum and Jefferies.",
Tripadvisor Announces Participation at Upcoming Conferences,2024-05-23T20:05:00.000Z,Low,Neutral,"Tripadvisor (NASDAQ: TRIP) announced its participation in two upcoming investor conferences. Mike Noonan, the company's CFO, will host investor meetings at the Bernstein 40th Annual Strategic Decisions Conference on May 30, 2024, in New York. Additionally, Noonan will represent Tripadvisor at the Mizuho Technology Conference on June 12, 2024, also in New York. These appearances aim to engage with investors and discuss the company's strategic and financial outlook.",
LuxUrban Hotels Announces Closing of Public Offering of Securities,2024-05-23T20:10:00.000Z,Low,Neutral,"LuxUrban Hotels closed its public offering of 35,075,000 shares of common stock, including the full exercise of the underwriters' over-allotment option, at $0.25 per share. The gross proceeds totaled approximately $8.8 million, before deducting underwriters' fees and expenses. Roth Capital Partners acted as the sole book-running manager, and Alexander Capital, L.P. was the co-manager. The proceeds will be used for working capital and general corporate purposes. The offering was conducted under a shelf registration statement declared effective on May 8, 2024, available on the SEC's website.",
"DATA Communications Management Corp. Report of Voting Results Annual Meeting of Shareholders Held on May 23, 2024",2024-05-23T20:09:00.000Z,Neutral,Neutral,"DATA Communications Management Corp. (TSX: DCM; OTCQX: DCMDF) held its annual shareholders meeting on May 23, 2024, in Toronto, Ontario. Representing 66.05% of the total votes, 29 shareholders with 36,489,348 shares participated. PricewaterhouseCoopers LLP was appointed as auditors with 100% approval.All eight directors proposed for election were successfully elected. The votes for the directors ranged from 87.18% to 99.93% in favor, highlighting broad shareholder support.",
Owlet to Participate in the 8th Annual Cowen Future of the Consumer Conference,2024-05-23T20:05:00.000Z,Low,Neutral,"Owlet, a leader in smart infant monitoring, announces its participation in the 8th Annual Cowen Future of the Consumer Conference in New York City, scheduled for June 4-5, 2024. The company’s Co-Founder and CEO, Kurt Workman, and CFO, Kate Scolnick, will present on June 5 at 10:10 a.m. Eastern Time. Owlet will also engage in one-on-one investor meetings. The presentation will be webcast live and available for replay on Owlet's Investor Relations website.",
Tyra Biosciences to Present at Upcoming Investor Conferences,2024-05-23T20:05:00.000Z,Low,Neutral,"Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm specializing in precision medicines for FGFR biology, will participate in several investor conferences. On May 28-29, 2024, CEO Todd Harris will join a fireside chat at TD Cowen's Oncology Innovation Summit. The company will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 5-6, 2024. Additionally, Harris will present on June 12, 2024, at the Goldman Sachs Global Healthcare Conference, with further investor meetings scheduled. Webcasts of these presentations will be available on Tyra's Investor page.",
AbbVie Completes Acquisition of Landos Biopharma,2024-05-23T20:05:00.000Z,Neutral,Neutral,"AbbVie has completed its acquisition of Landos Biopharma, enhancing its portfolio with NX-13, a first-in-class oral NLRX1 agonist currently in Phase 2 trials for treating ulcerative colitis (UC) and Crohn's disease (CD). The acquisition, priced at $20.42 per share plus up to $11.14 per share upon achieving a clinical milestone, aims to offer a novel, dual-action treatment approach to inflammatory bowel disease (IBD), combining anti-inflammatory properties and epithelial repair. Landos' stock will stop trading on NASDAQ from May 24, 2024. AbbVie expressed its commitment to transforming the standard of care for IBD patients.",
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference,2024-05-23T20:05:00.000Z,Low,Neutral,"Spruce Biosciences, a late-stage biopharmaceutical company specializing in therapies for rare endocrine disorders, will participate in the Jefferies Global Healthcare Conference.CEO Javier Szwarcberg will present on June 5, 2024, at 5:00 p.m. ET.The presentation will be accessible via a live webcast, with an archived version available for 90 days on the company's investor relations website.",
Altair to Present at Upcoming Investor Conferences,2024-05-23T20:05:00.000Z,Low,Neutral,"Altair (Nasdaq: ALTR), a leader in computational intelligence, announced that its Chief Financial Officer, Matt Brown, will participate in fireside chats at three upcoming investor conferences. These conferences include the William Blair Growth Stock Conference on June 5, 2024, in Chicago, IL at 12:40 p.m. CT, the Baird Global Consumer, Technology & Services Conference on June 6, 2024, in New York, NY at 11:25 a.m. ET, and the NASDAQ London Investor Conference in partnership with Jefferies on June 11, 2024, in London, ENG at 2:00 p.m. BST. A live webcast and replay of these presentations will be available on the company’s investor relations website.",
"Chuy’s Holdings, Inc. Announces Record Date and 2024 Annual Meeting of Stockholders",2024-05-23T20:05:00.000Z,Neutral,Neutral,"Chuy's Holdings (NASDAQ: CHUY) has announced the record date for its 2024 Annual Meeting of Stockholders as June 4, 2024. The meeting will be held on August 1, 2024, at 9:00 a.m. Central Time at Chuy's headquarters in Austin, Texas. Attendance is  to stockholders of record and beneficial owners who can provide proof of ownership as of the record date. Eligible attendees must present documentation such as an account statement, voting instruction card from a broker, bank, trustee, or nominee, or similar evidence of ownership.",
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results,2024-05-23T20:05:00.000Z,Moderate,Neutral,"23andMe Holding Co. (Nasdaq: ME) reported its FY24 Q4 and full-year results on May 23, 2024. Key highlights include a 31% decrease in Q4 revenue to $64 million and a 27% decline in full-year revenue to $220 million, primarily due to lower consumer services and research revenue. The company formed a Special Committee to review strategic alternatives and acknowledged CEO Anne Wojcicki's interest in acquiring outstanding shares. Operating expenses surged to $239 million in Q4, driven by a $153 million goodwill impairment charge. The net loss for Q4 was $209 million, and $667 million for the full year. However, the company advanced its clinical trials and launched new products. FY2025 guidance was not provided due to the ongoing strategic review.",
Defense Intelligence Agency (DIA) Selects Workday to Accelerate its Human Resources Modernization Efforts,2024-05-23T20:01:00.000Z,Low,Neutral,"Workday has announced that the Defense Intelligence Agency (DIA) has selected Workday Government Cloud for its HR modernization efforts. This is Workday's first major foray into the U.S. Intelligence Community, reflecting its growing influence in the U.S. Federal Government market. Partnering with reseller Groundswell, Workday aims to enhance DIA's recruitment and onboarding processes, centralize HR data, and boost employee engagement and retention. This initiative addresses the pressing need to modernize legacy technologies amidst rapid demographic changes and complex intelligence challenges. Workday's collaboration with DIA builds on its existing federal customer base and reinforces its commitment to federal market transformation.",
LPL Financial Reports Monthly Activity for April 2024,2024-05-23T20:05:00.000Z,Low,Neutral,"LPL Financial Holdings (Nasdaq: LPLA) announced its April 2024 activity report, revealing a 1.9% decline in total advisory and brokerage assets to $1.41 trillion, a drop of $27.9 billion from March 2024. Despite this, the company added $12 billion in net new assets, including $5 billion from the acquisition of Crown Capital. Organic net new assets grew by $7 billion, with advisory assets increasing by $7.4 billion. Client cash balances fell slightly by $0.6 billion to $45.7 billion, while net buying was $12.3 billion. Advisory assets decreased 2.2%, brokerage assets by 1.6%. The S&P 500 and Russell 2000 indices also saw declines of 4.1% and 7.1%, respectively.Important metrics include:Total advisory and brokerage assets: $1.41 trillionNet new assets: $12 billionOrganic net new assets: $7 billionClient cash balances: $45.7 billion",
Smith-Midland Reports Fourth Quarter and Year End 2023 Financial Results,2024-05-23T19:45:00.000Z,Neutral,Neutral,"Smith-Midland (NASDAQ: SMID) reported its highest ever quarterly and annual revenue for the fourth quarter and full year ending December 31, 2023. Q4 2023 revenue rose 13% to $16.4 million with product sales up 10% and service revenue up 17%. The company achieved an operating income of $542,000 and a net income of $230,000, or $0.04 per diluted share. For the full year, revenue increased 19% to $59.6 million. Operating income was up 31% to $1.1 million, while net income remained flat at $795,000, or $0.15 per diluted share, impacted by a significant state liability. Key highlights include a $3.8 million contract for J-J Hooks barriers and the addition of five new licensees in the U.S.",
"Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",2024-05-23T20:01:00.000Z,Low,Very Positive,"On May 23, 2024, Vaxart announced inducement equity awards granted on May 17, 2024, to a new non-executive employee. The awards include an option to purchase 15,000 shares of Vaxart’s common stock, vesting over four years, and 7,500 restricted stock units (RSUs), vesting 25% annually for four years. These awards were issued under Vaxart's 2024 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4). This plan is specifically used to attract new employees not previously with Vaxart or rejoining after a bona fide period of non-employment.",
Domino's Pizza® To Participate in Fireside Chat at Bernstein Strategic Decisions Conference,2024-05-23T20:00:00.000Z,Low,Neutral,"Domino's Pizza (NYSE: DPZ) will participate in the 40th Annual Strategic Decisions Conference hosted by Bernstein. The event will feature a fireside chat with CEO Russell Weiner, taking place on May 30, 2024, from 1:30 to 2:20 p.m. ET. Investors and stakeholders can view the live webcast through the provided link, and the event will be archived for future access. For further inquiries, contact Greg Lemenchick, Vice President of Investor Relations, at Greg.lemenchick@dominos.com.",
Ross Stores Reports First Quarter Earnings,2024-05-23T20:01:00.000Z,Neutral,Neutral,"Ross Stores (NASDAQ: ROST) reported its first quarter earnings for the 13 weeks ending May 4, 2024, with earnings per share (EPS) of $1.46 and net earnings of $488 million. This marks a significant increase compared to the previous year's EPS of $1.09 and net income of $371 million. The company's sales grew by 8% to $4.9 billion, and comparable sales rose by 3%.The operating margin improved to 12.2%, up from 10.1% in the last year's first quarter, attributed to lower distribution, incentive, and freight costs. Ross Stores repurchased 1.9 million shares for $262 million under a new $2.1 billion buyback authorization approved in March 2024.Looking ahead, Ross Stores forecasts comparable store sales to rise 2% to 3% for the second quarter ending August 3, 2024, with EPS projected to be between $1.43 to $1.49. For fiscal 2024, EPS is expected to range from $5.79 to $5.98, up from $5.56 in fiscal 2023.",
USANA Celavive Postbiotic Barrier Balm Named to Best in Skincare List,2024-05-23T18:44:00.000Z,Low,Neutral,"USANA Health Sciences announced that its Celavive Postbiotic Barrier Balm has been named to BELLA magazine's 2024 Best in Skincare award list. This recognition highlights the product's quality and effectiveness in catering to various skin types and concerns. The Postbiotic Barrier Balm, which features postbiotic Lactobacillus Ferment, cupuacu butter, and five ceramides, has been a top seller since its launch. USANA's executives expressed pride in this achievement, emphasizing the product's role in distinguishing the company in the competitive skincare market.",
Mastercard: How Kevin Kim's Immigrant Story Fuels NYC's Small Businesses,2024-05-23T18:00:00.000Z,Low,Very Positive,"Mastercard's recent press release highlights the impactful work of Kevin Kim, the commissioner of New York City's Department of Small Business Services (SBS). Kim, an immigrant from South Korea, has focused on improving outreach to immigrant small-business owners in NYC. Under his leadership, the SBS launched the $85 million NYC Small Business Opportunity Fund, which has provided loans to 1,046 businesses with an average amount of $80,000. Notably, 80% of these loans went to minority and women-owned businesses (MWBEs). Kim's initiatives have significantly contributed to the local economy, fostering optimism among small businesses. He plans to step down at the end of June, but his contributions have set a strong foundation for future growth.",
"Brandywine Realty Trust Announces Common Quarterly Dividend, and Confirms Second Quarter 2024 Earnings Release and Conference Call",2024-05-23T18:42:00.000Z,Low,Neutral,"Brandywine Realty Trust (NYSE:BDN) announced a quarterly cash dividend of $0.15 per common share and OP Unit, payable on July 18, 2024, to holders of record on July 3, 2024. This dividend equates to an annual rate of $0.60 per share. The company also confirmed it will release its second quarter 2024 earnings after the market closes on July 23, 2024. A conference call to discuss these results will be held on July 24, 2024, at 9:00 a.m. Eastern Time, accessible via phone and webcast.Brandywine Realty Trust is a leading REIT in the United States, operating primarily in Philadelphia and Austin, managing a portfolio of 156 properties and 22.3 million square feet as of March 31, 2024. The company focuses on urban, town center, and transit-oriented developments.",
Phoenix Motor Reschedules First Quarter 2024 Earnings Call to May 30,2024-05-23T19:00:00.000Z,Low,Neutral,"Phoenix Motor (Nasdaq:PEV), a leading manufacturer of heavy-duty transit buses and electrification solutions for medium-duty vehicles, rescheduled its first quarter 2024 earnings call to May 30, 2024, at 4:30 p.m. ET. The event will provide detailed financial results and updates, accessible via a live call or webcast. For those unable to attend, a replay will be available until June 13, 2024.",
Concord Acquisition Corp II Announces Transfer to NYSE American,2024-05-23T19:41:00.000Z,Neutral,Neutral,"Concord Acquisition Corp II (NYSE: CNDA) announced its decision to transfer the listing of its Class A common stock, units, and warrants from the New York Stock Exchange (NYSE) to NYSE American  (NYSE American). The transfer is scheduled to take effect on May 29, 2024. The stock, units, and warrants have been approved for listing on NYSE American and will retain their current ticker symbols CNDA, CNDA.U, and CNDA.WS. Until the transfer is finalized, trading will continue on the NYSE.",
Sego Resources Engages SRK Consulting for 3D Model and Mineral Inventory at the Southern Gold Zone,2024-05-23T18:30:00.000Z,Neutral,Neutral,"Sego Resources has engaged SRK Consulting to develop a 3D geological model and estimate the exploration target potential for the Southern Gold Zone at the Miner Mountain Project. This zone features fine-grained disseminated gold within altered intrusions and volcanics, extending from the surface down to a vertical depth of 80-100 meters. The mineralization zone measures approximately 280 by 140 meters. Significant drill intersections were reported, including a 59.11m interval with 1.03 g/t gold (DDH-46) and an 88.11m interval with 1.08 g/t gold (DDH-47). This initiative marks an essential step in advancing the exploration and development of Sego's copper-gold porphyry targets.",
"Trust Stamp files provisional patent for AI-based Age Estimation Calibration Algorithm, its 14th pending patent",2024-05-23T17:04:00.000Z,Moderate,Neutral,"Trust Stamp (Nasdaq: IDAI) has filed a provisional patent for a new AI-based Age Estimation Calibration Algorithm. This marks the company's 14th pending patent. The algorithm aims to enhance the accuracy and reliability of biometric-based age estimation, addressing regulatory demands and the need for effective age-restricted content verification. It builds on the Bayesian framework to manage age prediction uncertainties and allows tailoring of age category probabilities to client specifications. Chief Science Officer Dr. Norman Poh and President Andrew Gowasack highlight the algorithm's potential to outperform existing solutions, offering a more customized and precise age estimation for various client needs.",
PNC Bank Expands Community Advisory Council to 20 Members as It Strengthens Focus on Community Investment Needs Nationwide,2024-05-23T17:30:00.000Z,No impact,Positive,"PNC Bank has expanded its Community Advisory Council (CAC) to 20 members, adding nine executives representing seven states. The council, formed in 2022, supports PNC's $88 billion Community Benefits Plan aimed at fostering economic opportunity for low- and moderate-income individuals. The CAC advises PNC on community lending, investment, and service priorities, having already deployed nearly $56 billion in investments and loans. Newly appointed members will enhance PNC's impact on affordable housing and other critical needs. The council meets biannually to address issues affecting communities nationwide.",
Kroger Shares Graduation Party Staples for A+ Celebrations,2024-05-23T17:00:00.000Z,Low,Very Positive,"Kroger announced convenient and customizable party solutions for grad season. The retailer offers catering options such as custom cakes, sushi trays, deli meat and cheese platters, salads, fruits, veggies, and more. Customers can personalize graduation cakes and use Kroger’s cake calculator to find the perfect size. Party trays include fresh fruit, veggie trays, gourmet cheese packs, pretzel bites, and charcuterie with spinach artichoke dip. Kroger also provides grilling staples, sides, appetizers, drinks, and party supplies. Customers can shop these items in-store or via Kroger Pickup and Delivery, with additional savings through the Boost membership. Eligible customers can try Boost for free for 30 days, with savings on fuel and grocery delivery. Kroger Rewards World Elite Mastercard cardmembers can get a free one-year Boost membership.",
Peoples Ltd. Declares Second Quarter Dividend,2024-05-23T16:35:00.000Z,Low,Neutral,"Peoples  (OTC: PPLL) has announced a second quarter cash dividend of $0.62 per share. This dividend reflects an 8.98% increase over the same period last year. The dividend will be paid on June 28, 2024, to shareholders of record as of June 10, 2024. President and CEO Anthony J. Gabello made the announcement following the Board of Directors' regular meeting on May 22, 2024.",
Northrop Grumman to Participate in Bernstein’s 40th Annual Strategic Decisions Conference,2024-05-23T15:30:00.000Z,Low,Neutral,"Northrop Grumman (NYSE: NOC) is set to participate in Bernstein's 40th Annual Strategic Decisions Conference on May 30, 2024. The presentation by Kathy Warden, the company's chair, CEO, and president, will begin at 9:00 a.m. Eastern time and will be webcast live. Northrop Grumman, a prominent global aerospace and defense technology company, aims to provide innovative solutions to its customers, enhancing both connectivity and security. The company's focus is on pushing the boundaries of human exploration and solving complex problems daily.",
The Marcus Corporation Declares Quarterly Dividend,2024-05-23T15:42:00.000Z,Low,Neutral,"The Marcus  (NYSE: MCS) has announced a regular quarterly cash dividend of $0.07 per share of common stock, payable on June 26, 2024, to shareholders recorded by June 17, 2024. Additionally, a dividend of $0.064 per share will be paid on the Class B common stock, which is not publicly traded, also on June 26, 2024, to shareholders of record on June 17, 2024.The Marcus , based in Milwaukee, is a notable player in the lodging and entertainment sectors, with considerable real estate holdings. Their theatre division, Marcus Theatres, is the fourth largest in the U.S., operating 993 screens across 79 locations in 17 states. The lodging division, Marcus Hotels & Resorts, owns or manages 16 properties in eight states.",
"Rackspace Technology Further Establishes Market Leadership by Being Named Dell Technologies Global Alliances Service Provider of the Year, Americas",2024-05-23T15:05:00.000Z,Low,Positive,"Rackspace Technology (NASDAQ: RXT) has been named Dell Technologies Global Alliances Service Provider of the Year, Americas. This recognition highlights Rackspace's leadership in end-to-end, hybrid multicloud, and AI solutions. The award celebrates the successful collaboration between Rackspace and Dell, offering integrated solutions that address business and IT challenges, driving digital transformation, and providing value to customers. Adrianna Bustamante, VP of Private Cloud Partnerships, emphasized that this accolade underscores their efforts in hybrid multicloud, healthcare, and AI, enabling cost reductions, data control improvements, and new AI use cases while ensuring compliance and security.",
Viasat and Azercosmos to expand satellite services across EMEA and Asia,2024-05-23T15:47:00.000Z,Neutral,Neutral,"Viasat and Azercosmos have announced a cooperative effort to enhance satellite services across Africa, the Middle East, Europe, and Central and South Asia. This collaboration aims to deliver Viasat's L-band satellite services to Azerbaijan, supporting industries like energy, utilities, and transport. The services will include applications such as tracking and telemetry, pipeline monitoring, and environmental safety. This partnership will allow Azercosmos to expand its connectivity offerings and cater to a broader range of customers. The collaboration marks the first deployment of Viasat-enabled satellite services in Azerbaijan.Key executives from both companies highlighted the importance of this partnership in enhancing service reliability and expanding market reach.",
Global Pharmaceutical Services Leader Secures $12 Million in Financing from Wingspire Equipment Finance,2024-05-23T15:00:00.000Z,Neutral,Very Positive,"Wingspire Equipment Finance has completed a $12 million equipment financing arrangement for a leading pharmaceutical services company. The CDMO, supported by private equity, specializes in drug development, manufacturing, and commercial packaging. This financial package includes a capital lease and sale-leaseback, aimed at acquiring new manufacturing and packaging technology. The financing helps optimize cash flow and enhance liquidity, supporting the company's growth. Jason Alves, Senior VP at Wingspire, emphasized the importance of this partnership in meeting the client’s financial goals and ensuring their operational success.",
"Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma",2024-05-23T15:00:00.000Z,Moderate,Positive,"Biomica , a subsidiary of Evogene, released promising preliminary data from a Phase 1 trial of BMC128, a microbiome-based immuno-oncology candidate, in combination with nivolumab. This trial involves patients with refractory NSCLC, melanoma, or RCC. Key findings include an exceptional safety profile with no major safety events, 72% of refractory cases showing positive clinical signals, and 64% of patients demonstrating stable disease. Additionally, 55% of patients showed sustained clinical benefits beyond 16 weeks, with some exceeding 80 weeks. The data will be presented at the 2024 ASCO annual meeting.",
Annual Study Shows Wide Majority of Employees Want Workplace Support for Financial Challenges,2024-05-23T15:00:00.000Z,No impact,Neutral,"Morgan Stanley at Work's fourth annual State of the Workplace Financial Benefits Study reveals that employees increasingly seek workplace support for financial challenges. A significant majority of HR leaders (91%) believe employees face financial hardships, and nearly half of employees (46%) have experienced financial crises in the past year. These financial benefits are important for employee retention, with 87% of HR leaders citing them as key factors in employee decisions to stay. However, there is a gap in awareness and offering of these benefits, as 32% of employees have never sought help from their companies, and 82% of HR leaders recognize the need for more comprehensive solutions. Additionally, 82% of employees expect AI to transform their financial benefits experience. Morgan Stanley emphasizes the need for scalable, comprehensive solutions to support employees effectively.",
FC Barcelona Selects Fortinet as its Official Cybersecurity Partner for the Future Spotify Camp Nou,2024-05-23T15:00:00.000Z,Neutral,Positive,"FC Barcelona has partnered with Fortinet (NASDAQ: FTNT) as its Official Cybersecurity Partner for the next three seasons, until 30 June 2028. Fortinet's Security Fabric platform will secure digital environments at the future Spotify Camp Nou stadium, making it a global example of technology in sports and entertainment. This collaboration supports FC Barcelona's goal to turn Espai Barça into an international innovation hub. Fortinet's solutions will protect Wi-Fi, OT infrastructure, and data centers, enhancing security and efficiency. The partnership also aims to provide a superior experience for visitors and fans.",
Cadiz Posts Chairman and CEO Susan Kennedy's Webcast from Green Economy Conference VerdeXchange 2024,2024-05-23T14:33:00.000Z,Neutral,Neutral,"Cadiz, a California-based water solutions company, announced that its Chairman and CEO, Susan Kennedy, presented at the VerdeXchange 2024 conference on May 13, 2024. The event in Los Angeles featured Kennedy's talk titled 'Water Resiliency at Scale', which addressed climate change impacts on water resources in the Southwest U.S. and the company's innovative solutions in water supply, storage, conveyance, and treatment. VerdeXchange, in its 15th year, brings together industry leaders and policymakers to discuss developments in the green economy. The conference highlighted how regions can leverage $1.1 trillion in U.S. infrastructure funding for climate infrastructure investments. Kennedy's presentation is available on Cadiz's YouTube channel.",
